



Vaccines and Global Health: The Week in Review
02 April 2022 :: Issue 651
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. **This blog allows full text searching of over 23,000 entries.***

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director

Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

:: [Coronavirus \[COVID-19\] - WHO](#)

:: [Emergencies](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

Milestones - Perspectives

.....
.....

WHO Strategic Advisory Group of Experts on Immunization (SAGE) - April 2022

4 – 7 April 2022

:: [Draft agenda](#) [IA2030; Hepatitis A; COVID-19 Vaccines; Typhoid Update; HPV; Polio]

:: [SAGE Yellow Book](#)

.....
.....

Ukraine

Emergency in Ukraine: external situation report #5, published 31 March 2022: reporting period: 24–30 March 2022



Key updates

- On 24 March WHO started the establishment of a logistics hub in the city of Dnipro in collaboration with the United Nations High Commissioner for Refugees (UNHCR), the United Nations Office for the Coordination of Humanitarian Affairs (OCHA) and other United Nations (UN) partners, to facilitate the delivery of medical supplies and humanitarian assistance to areas in eastern Ukraine most severely affected by the ongoing conflict.
- WHO has developed tools to estimate the need for antiviral treatment and burden of tuberculosis (TB) among refugees from Ukraine to other countries. Both these tools are meant to support resource planning for the refugee-hosting countries. Based on the preliminary estimates, more than 30 000 people living with HIV may need HIV services in refugee-hosting countries.
- In Poland WHO conducted a joint mission to assess the availability and accessibility of health services in the border region of Lublin on 25–26 March.
- In the Republic of Moldova, WHO and the MoH conducted a rapid assessment of the health services available to refugees on 27 March...

[Excerpts]

"...Vaccination for COVID-19 has been disrupted. Prior to the conflict at least 50 000 people per day were receiving vaccination. This number has dropped significantly, with only 175 000 people being vaccinated between 24 February and 15 March despite suboptimal vaccination coverage. Between 23 February and 30 March, the overall number of beds available and beds occupied by patients with COVID-19 has decreased by 29% and 85% respectively, reflecting potential challenges in accessing hospitals, limited data reporting, and a potential decrease in actual hospitalizations following the peak of the Omicron wave earlier in February...

"...Suboptimal vaccination coverage for routine and childhood immunizations, including measles and poliomyelitis (polio), increases the risk of re-emergence and transmission of vaccine-preventable diseases. Notably, two cases of circulating vaccine-derived poliovirus type 2 (cVDPV2) were reported in Ukraine in 2021. On 1 February 2022 a national supplemental polio immunization campaign targeting nearly 140 000 children was launched, but due to the current situation it has been deprioritized and significantly slowed down.³ ..."

.....
.....

Featured Journal Content

Science

Volume 376| Issue 6588| 1 Apr 2022

<https://www.science.org/toc/science/current>

Special issue - Completing the human genome

Introduction to Special Issue

Filling the gaps

BY Laura M. Zahn

31 Mar 2022: 42-43

A fully sequenced human genome was triumphantly announced more than 20 years ago. However, owing to technological limitations, some genomic regions remained unresolved. Here, Science presents research by the Telomere-to-Telomere (T2T) Consortium, reporting on the endeavor to complete a comprehensive human reference genome. Generated primarily by long-read sequencing of a hydatidiform mole, a doubly haploid growth, this effort adds ~200 megabases of genetic information—a full chromosome's worth—to the human genome.

Through the resolution of previously unsequenceable and unalignable regions, mostly composed of highly repetitive sequences, this reference genome allows for a detailed characterization of the centromeric satellite repeats, transposable elements, and segmental duplications. Mapping of genomic sequences, including those from previously published studies, resolves aspects of human genetic diversity, including evolutionary comparisons with our primate relatives. Furthermore, it allows for identification of how changes in methylation density differ within and among centromeres and how epigenetics can affect the transcription of repeat sequences.

These investigations have only begun to tease apart how the T2T reference genome influences the detection of biomedically relevant variants and the evolution of genomic regions that determine human traits. Although much remains to be discovered, the T2T reference genome provides another celebratory benchmark to observe as we continue to delve into the genetics that underlie our complete selves.//

The complete sequence of a human genome

BY Sergey Nurk et al [89 authors]

31 Mar 2022: 44-53

Abstract

Since its initial release in 2000, the human reference genome has covered only the euchromatic fraction of the genome, leaving important heterochromatic regions unfinished. Addressing the remaining 8% of the genome, the Telomere-to-Telomere (T2T) Consortium presents a complete 3.055

billion–base pair sequence of a human genome, T2T-CHM13, that includes gapless assemblies for all chromosomes except Y, corrects errors in the prior references, and introduces nearly 200 million base pairs of sequence containing 1956 gene predictions, 99 of which are predicted to be protein coding. The completed regions include all centromeric satellite arrays, recent segmental duplications, and the short arms of all five acrocentric chromosomes, unlocking these complex regions of the genome to variational and functional studies.

.....

NIH - [Researchers generate the first complete, gapless sequence of a human genome](#) -
Completion is critical for understanding the full spectrum of human genomic variation and for understanding the genetic contributions to certain diseases.

March 31, 2022 — Scientists have published the first complete, gapless sequence of a human genome, two decades after the Human Genome Project produced the first draft human genome sequence.

According to researchers, **having a complete, gap-free sequence of the roughly 3 billion bases (or “letters”) in our DNA is critical for understanding the full spectrum of human genomic variation and for understanding the genetic contributions to certain diseases.**

The work was done by the Telomere to Telomere (T2T) consortium, which included leadership from researchers at the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health; University of California, Santa Cruz; and University of Washington, Seattle. NHGRI was the primary funder of the study.

Analyses of the complete genome sequence will significantly add to our knowledge of chromosomes, including more accurate maps for five chromosome arms, which opens new lines of research. This helps answer basic biology questions about how chromosomes properly segregate and divide. The T2T consortium used the now-complete genome sequence as a reference to discover more than 2 million additional variants in the human genome. These studies provide more accurate information about the genomic variants within 622 medically relevant genes.

“Generating a truly complete human genome sequence represents an incredible scientific achievement, providing the first comprehensive view of our DNA blueprint,” said Eric Green, M.D., Ph.D., director of NHGRI. “This foundational information will strengthen the many ongoing efforts to understand all the functional nuances of the human genome, which in turn will empower genetic studies of human disease.”...

The full sequencing builds upon the [work of the Human Genome Project](#), which mapped about 92% of the genome, and research undertaken since then. Thousands of researchers have developed better laboratory tools, computational methods and strategic approaches to decipher the complex sequence. Six papers encompassing the completed sequence appear in [Science\(link is external\)](#), along with companion papers in several other journals.

That last 8% includes numerous genes and repetitive DNA and is comparable in size to an entire chromosome. Researchers generated the complete genome sequence using a special cell line that has two identical copies of each chromosome, unlike most human cells, which carry two slightly different copies. The researchers noted that most of the newly added DNA sequences were near the

repetitive telomeres (long, trailing ends of each chromosome) and centromeres (dense middle sections of each chromosome).

"Ever since we had the first draft human genome sequence, determining the exact sequence of complex genomic regions has been challenging," said Evan Eichler, Ph.D., researcher at the University of Washington School of Medicine and T2T consortium co-chair. "I am thrilled that we got the job done. The complete blueprint is going to revolutionize the way we think about human genomic variation, disease and evolution."...

According to consortium co-chair Adam Phillippy, Ph.D., whose research group at NHGRI led the finishing effort, sequencing a person's entire genome should get less expensive and more straightforward in the coming years.

"In the future, when someone has their genome sequenced, we will be able to identify all of the variants in their DNA and use that information to better guide their healthcare," Phillippy said. "Truly finishing the human genome sequence was like putting on a new pair of glasses. Now that we can clearly see everything, we are one step closer to understanding what it all means."

Many early-career researchers and trainees played pivotal roles, including researchers from Johns Hopkins University, Baltimore; University of Connecticut, Storrs; University of California, Davis; Howard Hughes Medical Institute, Chevy Chase, Maryland; and the National Institute of Standards and Technology, Gaithersburg, Maryland. The package of six papers reporting this accomplishment appears in today's issue of *Science*, along with companion papers in several other journals.

For more, visit [Genome.gov/T2T](https://www.genome.gov/T2T)(link is external) and follow [@Genome_gov](https://twitter.com/Genome_gov)(link is external).

.....
.....

WHO releases 10-year strategy for genomic surveillance of pathogens

One in three countries do not have the capacity to use this critical tool

30 March 2022 *News release*

...Genomic surveillance is the process of constantly monitoring pathogens and analyzing their genetic similarities and differences. It helps researchers, epidemiologists and public health officials to monitor the evolution of infectious diseases agents, alert on the spread of pathogens, and develop counter measures like vaccines.

The *Global genomic surveillance strategy for pathogens with pandemic and epidemic potential 2022–2032* is not specific to a single pathogen or disease threat. It provides a high-level unifying framework to leverage existing capacities, address barriers and strengthen the use of genomic surveillance worldwide.

Data collected by WHO show that in March 2021, 54% of countries had this capacity. By January 2022, thanks to the major investments made during the COVID-19 pandemic, the number had increased to 68%. Even greater gains were made in the public sharing of sequence data: in January 2022, 43% more countries published their sequence data compared to a year before.

Despite this fast progress, much remains to be done. Any new technology comes with the risk of increasing inequity, which is one of the gaps this strategy targets. Various public health programmes – from Ebola to cholera – use genomic surveillance to understand a pathogen at its molecular level, but COVID-19 has highlighted the challenges of bringing genomics to scale.

Dr Tedros Adhanom Ghebreyesus, WHO Director-General, said, “The complexities of genomics and the challenges of sustaining capacities in different settings, including workforce needs, means that most countries cannot develop these capabilities on their own. The global strategy helps keep our eyes on the horizon and provides a unifying framework for action. WHO looks forward to working with countries and partners in this important and highly dynamic field,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “We will do best if we work together.”...

[Global genomic surveillance strategy for pathogens with pandemic and epidemic potential, 2022–2032 \[WHO\]](#)

28 March 2022 32 pages

The Strategy provides a high-level unifying framework to leverage existing capacities, address barriers and strengthen the use of genomic surveillance in the detection, monitoring and response to public health threats. Genomic surveillance is part of the broader surveillance and laboratory system, and its implementation should reinforce end-to-end capacities including sample collection, diagnostics, data sharing and analysis. The strategy aims to facilitate the connectivity between different disease control programs and surveillance networks. This interoperability will strengthen the cross-cutting essential public health laboratory functions underpinning genomics holistically. The strategy articulates the overarching goal, objectives and strategic actions needed. These are dependent on commitments from countries, partners and WHO for their implementation.

.....
.....

Featured Journal Content

The Journal of Infectious Diseases

Accepted manuscript

[The Concept of Classical Herd Immunity May Not Apply to COVID-19](#)

David M Morens, Gregory K Folkers, Anthony S Fauci

jia109, <https://doi.org/10.1093/infdis/jia109>

Published: 31 March 2022

PDF only: <https://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jia109/43207935/jia109.pdf>

[Opening Paragraphs]

There has been speculation about when in the COVID-19 pandemic we will be able to live with the virus in a manner that does not disrupt most peoples' lives. Much of this discussion has focused on herd immunity thresholds:

A herd immunity threshold is the proportion of a population with immunity against a communicable disease agent (resulting from innate immunity, natural infection, or vaccination) above which transmission of the agent is largely prevented, except for sporadic outbreaks in under-vaccinated or otherwise incompletely protected subsets of individuals.

As commonly understood [1-7], herd immunity thresholds are reached when a sufficient proportion of the population is vaccinated or has recovered from natural infection with a pathogen such that its community circulation is reduced below the level of significant public health threat. For example, this threshold has been met with polio and measles circulation in the United States.

However, SARS-CoV-2, the virus that causes COVID-19, is so different from polio and measles that classical herd immunity may not readily apply to it. Important differences include the phenotypic stability of polio and measles viruses, and their ability to elicit long-term protective immunity, compared to SARS-CoV-2. For these and other reasons, controlling COVID-19 by increasing herd immunity may be an elusive goal...

[Closing Section]

HERD IMMUNITY AND COVID-19.

There are significant obstacles to achieving complete herd immunity with COVID-19.

"Classical" herd immunity, leading to disease eradication or elimination, almost certainly is an unattainable goal. As noted, mass vaccination and aggressive public health approaches have struggled to control other (seemingly more controllable) respiratory infectious diseases, such as smallpox, measles, and rubella, all caused by viruses with limited phenotypic evolution. Controlling SARS-CoV-2 and its cycles of new variants presents a much more formidable challenge *23+. Like influenza, SARS-CoV-2 mutates continually into new variants that can escape immunity derived from infections and vaccines. It also can be transmitted asymptotically and without pathognomonic signs, impeding public health control. SARS-CoV-2 appears not to substantially engage the systemic immune system, as do viruses such as smallpox, measles, and rubella that consistently have a pronounced viremic phase. Moreover, neither infection nor vaccination appears to induce prolonged protection against SARS-CoV-2 in many or most people. Finally, the public health community has encountered substantial resistance to efforts to control the spread of SARS-CoV-2 by vaccination, mask wearing, and other interventions.

If vaccine- or infection-induced immunity to SARS-CoV-2 indeed proves to be short-lived, or if escape mutants continue to emerge, viral spread may continue indefinitely, albeit hopefully at a low endemic level. This notably has occurred with the 1918 pandemic influenza virus, whose viral descendants still are causing seasonal outbreaks and occasional pandemics 104 years later (pandemic H2N2 in 1957, H3N2 in 1968, and H1N1 in 2009) (24), and which we have been unable, after more than 80 years of trying, to fully control with vaccines. Such factors probably make SARS-CoV-2 impossible to eradicate (only one human virus – smallpox -- has ever been eradicated), difficult to eliminate over long periods within large geographic areas, and difficult to satisfactorily control even with good vaccines.

Thus, COVID-19 is likely to be with us, even if at a very low level of endemic community spread and with lower severity, for the foreseeable future. Like influenza, any level of herd protection against SARS-CoV-2 potentially can be overcome by ever-changing levels of immunity among countless sub-populations, by human movement, crowding, changes in social or prevention behaviors, by demographics, by vaccination levels, by variations in durability of infection- or vaccine-induced immunity, and by evolution of viral variants, among many other variables.

But encouragingly, after more than two years of viral circulation, and more than a year of vaccines with boosters, **we now have a high degree of background population immunity to SARS-CoV-2,**

as well as medical countermeasures such as antiviral drugs and monoclonal antibodies to prevent progression of disease, and widely available diagnostic tests. With these interventions we can aspire to, and very likely will succeed in achieving, substantial control of community spread without the disruptions of society caused by COVID-19 over the past 2 years. **We no longer need the elusive concept of “herd immunity” as an aspirational goal: COVID-19 control is already within our grasp.**

Looking forward, more broadly protective vaccines could play important roles in controlling SARS-CoV-2 and its inevitable variants. **Developing “universal” coronavirus vaccines (or at least universal SARS-CoV-2 vaccines that elicit durable and broadly protective immunity against multiple SARS-CoV-2 variants) is an important goal for the immediate future** (23). Meanwhile, optimal COVID-19 control will require both classic, non-pharmacologic public health approaches and vaccination of many more people globally with the SARS-CoV-2-specific vaccines we already have, with booster shots and with updates to vaccine antigens if needed.

Living with COVID is best considered not as reaching a numerical threshold of immunity, but as optimizing population protection without prohibitive restrictions on our daily lives. Effective tools for prevention and control of COVID-19 (vaccines, prevention measures) are available; if utilized, the road back to normality is achievable even without achieving classical herd immunity.

.....
.....
.....

Coronavirus [COVID-19] - WHO

Public Health Emergency of International Concern (PHEIC)

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

Weekly Epidemiological and Operational updates

Last update: 01 Apr 2022

Confirmed cases :: 486 761 597

Confirmed deaths :: 6 142 735

Vaccine doses administered: 11 054 362 790

.....

Weekly epidemiological update on COVID-19 - 29 March 2022

Overview


Between the end of January and early March 2022, there was a consistent decreasing trend in the number of new COVID-19 cases, which was followed by two consecutive weeks of increase in cases. During the week of 21 through 27 March 2022, the number of new cases declined again with a 14% decrease as compared to the previous week. On the other hand, during the same period, the number of new weekly deaths has increased by 43%, driven by changes in the definition of COVID-19 deaths in countries in the Region of the Americas (Chile and the United States of America) and retrospective adjustments reported from India in the South-East Asia Region.

Across the six WHO regions, over 10 million new cases and over 45 000 new deaths were reported. All regions reported decreasing trends in the number of new weekly cases and four regions reported a

decreasing trend in new weekly deaths. As of 27 March 2022, over 479 million confirmed cases and over 6 million deaths have been reported globally.

In this edition, we provide updates on the geographic distribution of circulating SARS-CoV-2 variants of concern (VOCs), including information on recombinant variants.

Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 27 March 2022**



■■■■■
■■■■■

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 02 March 2022

[New additions; Full scale view available at title link above]

[Updated on 02 Apr 2022]

	Manufacturer / WHO EUL holder	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Decision date***
14.	NOVAVAX	NVX-CoV2373/Nuvaxovid	EMA	Recombinant nanoparticle prefusion spike protein formulated with Matrix-M™ adjuvant	✓	✓	Rolling data started 19 August 2021	Finalized	20 December 2021
15.	RUSSIAN DIRECT INVESTMENT FUND	Sputnik V	Russian NRA	Human Adenovirus Vector-based Covid-19 vaccine	Additional information submitted	Several meetings have been and continue to be held.	"Rolling" submission incomplete.	Process restarted, awaiting completion of rolling submission and CAPAs to last inspection	Anticipated date will be set once all data is submitted and follow-up of inspection observations completed.
16.	Sinopharm / WIBP ¹	Inactivated SARS-CoV-2 Vaccine (Vero Cell)	NMPA	Inactivated, produced in Vero cells	✓	✓	Rolling data started 23 July 2021	Ongoing	To be confirmed
17.	康希诺生物 CanSinoBIO	Ad5-nCoV	NMPA	Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)	✓	✓	Rolling data started 09 August 2021	Ongoing	TBC
18.	SANOFI	CoV2 preS dTM-AS03 vaccine	EMA	Recombinant, adjuvanted	✓	✓	Rolling data started 30 July 2021	Ongoing	TBC
19.	Clover Biopharmaceuticals	SCB-2019	NMPA	Novel recombinant SARS-CoV-2 Spike (S)-Trimer fusion protein	✓	✓	Rolling data started 20 September	Ongoing	
20.	Zhifei Longcom, China	Recombinant Novel Coronavirus Vaccine (CHO Cell)	NMPA	Recombinant protein subunit	✓	2 Pre-submission meeting held on 1 and 21 Dec 2021	Rolling data started 28 March 2022		
21.	Shifa Pharmed - Barkat	Coviran® vaccine	Iran Food Drug Administration (IFDA)	Inactivated, produced in Vero cells	✓	Presubmission meeting held on 26 January 2022	Rolling data starting week of 30 March 2022		
22.	CIGB	Abdala	CECMED	Protein subunit	✓				
23.	Biological E	Corbevax	DCGI India	RBD antigen of SARS-CoV-2 (Covid-19)	EOI under review				
24.	SK Bioscience	GBP510	MFDS (RoKorea)	Recombinant protein subunit	EOI under review				
25.	WestVac Biopharma	Recombinant COVID-19 Vaccine	NMPA China	Recombinant SARS-CoV-2 S-RBD protein	EOI under review				
26.	Nanogen	Nanocovax	Drug Administration of Vietnam	Recombinant Spike protein	EOI under review				
27.	Cinnagen	SpikoGen	Iran Food Drug Administration (IFDA)	Recombinant Protein	EOI under review				
28.	R-PHARM	Vaccine R-COVI	Russian NRA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	EOI under review				
29.	SK Bioscience	Nuvaxovid prefilled syringe	MFDS (RoKorea)	Recombinant nanoparticle prefusion spike protein formulated with Matrix-M™ adjuvant	EOI under review				
30.	Medicago	COVIFENZ®	Health Canada	Plant-based virus-like particle [VLP], recombinant, adjuvanted	Not accepted				
31.	LUNEVAC	Zorecimeran (INN) concentrate and solvent for dispersion for injection; Company code: CVnCoV/CV07050101	EMA	mRNA-based vaccine encapsulated in lipid nanoparticle (LNP)	✓	Application withdrawn by manufacturer			
32.	Vector State Research Centre of Virology and Biotechnology	EpiVacCorona	Russian NRA	Peptide antigen	Letter received not EOI. Reply sent on 15/01/2021				
33.	IMBCAMS, China	SARS-CoV-2 Vaccine, Inactivated (Vero Cell)	NMPA	Inactivated	Not accepted, still under initial development				
34.	BioCubaFarma - Cuba	Soberana 01, Soberana 02, Soberana Plus	CECMED	SARS-CoV-2 spike protein conjugated chemically to meningococcal B or tetanus toxoid or Aluminum	Awaiting information on strategy and timelines for submission.				

1. Beijing Institute of Biological Products Co-Ltd
2. Wuhan Institute of Biological Products Co Ltd

* Dossier Submission dates: more than one date is possible because of the rolling submission approach. Dossier is accepted after screening of received submission.

**Status of assessment: 1. Under screening; 2. Under assessment; 3. Waiting responses from the applicant. 4. Risk-benefit decision 5. Final decision made

*** Anticipated decision date: this is only an estimate because it depends on when all the data is submitted under rolling submission and when all the responses to the assessors' questions are submitted.

Please send any questions you may have to: WHO.EUL@who.int

COVID Vaccines/Therapeutics - Developer/Manufacturer Announcements

[Selected press releases/announcements from organizations from WHO EUL/PQ listing above and other organizations]

AstraZeneca

Press Releases

[Evusheld long-acting antibody combination approved in the EU for pre-exposure prophylaxis \(prevention\) of COVID-19 in a broad population](#)

28 March 2022

Bharat Biotech

Press Releases - No new digest announcements identified

BioCubaFarma – Cuba

Últimas Noticias - Website not leading at inquiry

Biological E

News - No new digest announcements identified

Biontech

Press Releases

[**Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older**](#)

29 Mar 2022

CanSinoBIO

News - Website not responding at inquiry

CIGB

Latest News

[**Purity and efficacy of Mambisa, the first anti-covid nasal vaccine \(Part I\)**](#)

09 Mar 2022

Cinagen

Recent News - No new digest announcements identified

Clover Biopharmaceuticals - China

News - No new digest announcements identified

Curevac [Bayer Ag – Germany]

News

March 30, 2022

[**CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV**](#)

- Phase 1 dose-escalation study started at clinical sites in the U.S.
- Milestone demonstrates CureVac's and GSK's continued execution on comprehensive clinical program of second-generation vaccine candidates for infectious diseases

Gamaleya National Center

Latest News and Events - See Russia below.

IMBCAMS, China

Home - Website not responding at inquiry

Janssen/JNJ

Press Releases

Mar 29, 2022 United States

[**U.S. FDA Approves CABENUVA \(cabotegravir and rilpivirine\) for Adolescents, Expanding the Indication of the First and Only Complete Long-Acting Injectable HIV Regimen**](#)

Medicago

Media

February 24, 2022

[Medicago and GSK announce the approval by Health Canada of COVIFENZ®, an Adjuvanted Plant-Based COVID-19 Vaccine](#)

Moderna

Press Releases

March 29, 2022

[Moderna Receives FDA Approval for Emergency Use Authorization of 2nd Booster Dose of Its COVID-19 Vaccine, mRNA-1273](#)

Nanogen

News - No new digest announcements identified

Novavax

Press Releases

[Novavax Statement on Arrival of its COVID-19 Vaccine in Canada](#)

Mar 31, 2022

[Novavax Submits Request to Expand Conditional Marketing Authorization of COVID-19 Vaccine in the European Union to Adolescents \(Ages 12-17\)](#)

Mar 31, 2022

Pfizer

Recent Press Releases

03.29.2022

[Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older](#)

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Sanofi Pasteur

Press Releases - No new digest announcements identified

Serum Institute of India

NEWS & ANNOUNCEMENTS - No new digest announcements identified

Shifa Pharmmed [Iran]

<http://shafapharmed.com/>

No news page identified.

Sinopharm/WIBPBIBP

News - No new digest announcements identified

Sinovac

Press Releases - No new digest announcements identified

Vector State Research Centre of Virology and Biotechnology

Home - No new digest announcements identified

WestVac Biopharma

Media - No new digest announcements identified

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[No website identified]

.....

GSK

Press releases for media - No new digest announcements identified

Merck

News releases - No new digest announcements identified

Novartis

News - No new digest announcements identified

SK Biosciences

Press releases - Website not responding at inquiry

Valneva

Press Releases - No new digest announcements identified

.....

.....

[UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 02 Apr 2022](#)

An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 10/22/2021 reported]



35

vaccines approved for use by at least one national regulatory authority ¹



10

vaccines in WHO's Emergency Use Listing



17.8bn

doses secured globally



\$2-\$40

reported vaccine price range per dose



2.8bn

doses COVAX has secured, optioned, or received as donations



1.40bn

doses shipped through COVAX to 145 countries


.....

.....

COVID-19 Global Targets and Progress Tracker - IMF

The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges.

Daily Vaccination Rate Needed to Reach 70% by Mid-2022, assuming 2-dose vaccines (per 100 people)




The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.

.....
.....

Global Dashboard on COVID-19 Vaccine Equity

The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 02 Apr 2022]: <https://data.undp.org/vaccine-equity/>
See also visualization on [Vaccine Access](#) and [Vaccine Affordability](#)




.....

■■■■■

Global COVID-19 Access Tracker

<https://www.covid19globaltracker.org/>



■■■■■

■■■■■

Duke – Launch and Scale Speedometer

The Race for Global COVID-19 Vaccine Equity

A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution [accessed 24 July 2021]

[See our COVID Vaccine Purchases research](#)

[See our COVID Vaccine Manufacturing research](#)

[See our COVID Vaccine Donations & Exports research](#)

Overview of donations by top 10 donating countries

Bar chart is ordered by total number of doses pledged.



Donut charts are ordered by proportion of pledged donations shipped.

Country Category:

Top 10 Donating Countries

Pledged doses

Total Shipped



Data updated on Apr 1st 2022

Duke GLOBAL HEALTH
Innovation Center

.....
.....

COVID Vaccines – OCHA:: HDX

[COVID-19 Data Explorer: Global Humanitarian Operations](#)

COVID-19 Vaccine Roll-out

02 Apr 2022 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | [DATA](#)

Global COVID-19 Figures: 487M total confirmed cases; 6.1M total confirmed deaths

Global vaccines administered: 11.3B

Number of Countries: 28

COVAX Allocations Round 4-9 (Number of Doses): 170M

COVAX Delivered (Number of Doses): 280M

Other Delivered (Number of Doses): 260M

Total Delivered (Number of Doses): 540M

Total Administered (Number of Doses): 380M

.....
.....


Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]

<https://data.covid19taskforce.com/data>

A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.

Website accessed **02 Apr 2022**: <https://data.covid19taskforce.com/data> The global view below is complemented by country-specific dashboards [here](#).



.....
.....

Our World in Data


Coronavirus (COVID-19) Vaccinations [Accessed 02 Apr 2022]

- [64.5%](#) of the world population has received at least one dose of a COVID-19 vaccine.
- [11.29 billion doses](#) have been administered globally, and [18.7 million](#) are now administered each day.
- Only [14.5%](#) of people in low-income countries have received at least one dose.

Share of people who completed the initial COVID-19 vaccination protocol, Mar 31, 2022

Our World
in Data

Total number of people who received all doses prescribed by the initial vaccination protocol, divided by the total population of the country.



Source: Official data collated by Our World in Data - Last updated 1 April 2022, 11:00 (London time)

Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.

OurWorldInData.org/coronavirus • CC BY


Dec 13, 2020 Mar 31, 2022

Share of people who completed the initial COVID-19 vaccination protocol, Mar 31, 2022

Our World
in Data

Total number of people who received all doses prescribed by the initial vaccination protocol, divided by the total population of the country.

+ Add country



Source: Official data collated by Our World in Data - Last updated 1 April 2022, 11:00 (London time)

Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.

OurWorldInData.org/coronavirus • CC BY

Dec 13, 2020 Mar 31, 2022

.....
.....

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

HHS

News

[Statement from HHS Secretary Xavier Becerra on FDA and CDC Expanding Booster Eligibility for the Most Vulnerable](#)

March 29, 2022 | News Release

BARDA – U.S. Department of HHS [to 02 Apr 2022]

<https://aspr.hhs.gov/newsroom/Pages/NewsRoomHome.aspx>

News

[ASPR Announcement - New COVID-19 Treatment Locator Now Available!](#)

Wednesday, March 30, 2022

.....

FDA

Press Announcements

[March 29, 2022 - Coronavirus \(COVID-19\) Update: FDA Authorizes Second Booster Dose of Two COVID-19 Vaccines for Older and Immunocompromised Individuals](#)

Vaccines and Related Biological Products Advisory Committee- FDA

<https://www.fda.gov/advisory-committees/blood-vaccines-and-other-biologics/vaccines-and-related-biological-products-advisory-committee>

Calendar

[Vaccines and Related Biological Products Advisory Committee Meeting April 6, 2022 Announcement - 04/06/2022](#)

The committee will meet in open session to discuss considerations for use of COVID-19 vaccine booster doses and the process for COVID-19 vaccine strain selection to address current and emerging variants.

.....

White House [U.S.] [to 02 Apr 2022]

Briefing Room – Selected Major COVID Announcements

[Remarks by President Biden on the Status of the Country's Fight Against COVID-19](#)

March 30, 2022 • Speeches and Remarks

[Fact Sheet: Biden Administration Launches COVID.gov, a New One-Stop Shop Website for Vaccines, Tests, Treatments, Masks, and the Latest COVID-19 Information](#)

March 30, 2022 • Statements and Releases

U.S. Department of State [to 02 Apr 2022]

<https://www.state.gov/coronavirus/releases/>

Press Statement - COVID Context

No new digest content identified.

USAID [to 02 Apr 2022]

<https://www.usaid.gov/news-information/press-releases>

Selected Press Releases, Statements, Announcements

[Humanitarian Convoys Transport Emergency Food Aid for More Than 100,000 People in Tigray and Afar](#)

April 1, 2022

This week, two humanitarian convoys from U.S. Agency for International Development (USAID) partner UN World Food Program (WFP) transported emergency food aid to the Tigray and Afar regions of northern Ethiopia, including the first convoy to Tigray in more than three and a half months. This emergency food aid will support more than 100,000 people in northern Ethiopia. The arrival of the convoys is an important development in the effort to provide life-saving assistance to the people of Tigray and Afar, as only road transport can deliver the scale of assistance needed across northern Ethiopia. USAID commends the federal and regional Ethiopian authorities, as well as local communities, which worked together to make this first step possible. USAID urges all parties to ensure sustained and significant access for the delivery of life-saving assistance in these regions, as well as the neighboring Amhara region.

[The U.S. Strategy to Prevent Conflict and Promote Stability: Priority Countries and Region](#)

April 1, 2022

The U.S. government is moving forward in the spirit of partnership with four countries and a regional grouping of countries to implement the ten-year U.S. Strategy to Prevent Conflict and Promote Stability. This represents an important milestone and next step in the realization of the goals of the landmark Global Fragility Act, which continues to enjoy strong bipartisan Congressional support for innovative efforts to foster a more peaceful and stable world. In light of the horrific events unfolding in Ukraine caused by Putin's unprovoked and brutal war, the United States reaffirms its commitment to strengthen global resiliency and democratic renewal, and promote peaceful, self-reliant nations that become U.S. economic and security partners.

[The United States Provides Nearly \\$204 Million in New Funding to Address the Humanitarian Crisis in Afghanistan](#)

March 31, 2022

Today at the United Nations Office for the Coordination of Humanitarian Affairs, United Kingdom, Germany, and Qatar-hosted virtual pledging conference, the United States announced it is providing nearly \$204 million in additional humanitarian assistance for the people of Afghanistan. This funding includes over \$70 million through the U.S. Agency for International Development (USAID), and continues America's enduring support of the Afghan people, bringing the total U.S. humanitarian assistance for Afghanistan to more than \$4.6 billion since 2002, the largest amount of assistance from any country.

[The United States Announces More Than \\$152 Million in Additional Humanitarian Assistance for the People of Burma and Bangladesh](#)

March 29, 2022

Today, the United States announced more than \$152 million in additional humanitarian assistance for the Rohingya humanitarian crisis, including support for those affected by ongoing violence in Burma, refugees from Burma in Bangladesh, and Bangladeshi host communities. This funding includes more than \$101 million from the U.S. Agency for International Development (USAID) and nearly \$51 million from the U.S. Department of State. It brings the total U.S. humanitarian assistance to the crisis to more than \$1.7 billion since August 2017.

.....
.....

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency

[News & Press Releases](#)

[Press Releases](#)

[News: Advice to sponsors on managing the impact of the war in Ukraine on clinical trials \(new\)](#)

Last updated: 30/03/2022

[News: EU recommendations for 2022-2023 seasonal flu vaccine composition \(new\)](#)

CHMP, Last updated: 29/03/2022

[News: EMA starts rolling review of COVID-19 Vaccine HIPRA \(PHH-1V\) \(new\)](#)

CHMP, Last updated: 29/03/2022

.....

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

[Latest Updates \[Selected\]](#)

[No new digest content identified]

.....



European Centre for Disease Prevention and Control

COVID-19 Vaccine Tracker

At least one dose	Primary course	Booster/additional dose
75.2%	72.4%	52.5%

Cumulative vaccine uptake (%) in the total population in EU/EEA countries as of 2022-03-31

by reporting week (data for the current week are preliminary)

Accessed 02 Apr 2022

<https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab>

.....

European Commission

<https://ec.europa.eu/commission/presscorner/home/en>

Latest [Selected]

Press release 31 March 2022

[Afghanistan, Iran, Pakistan: EU releases €113 million in humanitarian support](#)

During the Afghanistan Pledging Conference today, the Commission will announce €113 million in EU humanitarian assistance for the Afghan people, addressing the urgent needs in Afghanistan and the region.

Press release 29 March 2022

[Humanitarian aid: EU releases €48.4 million to support people in Bangladesh, Myanmar and the region](#)

The European Commission has announced today €48.4 million in humanitarian aid to address the most pressing needs of people in Bangladesh, Myanmar and the region facing displacement, the consequences of protracted conflict and the ongoing Rohingya refugee crisis.

.....

[European Union funding boosts COVID-19 vaccination in Africa](#)

29 March 2022

A contribution of €16 million from the European Commission's Directorate-General for European Civil Protection and Humanitarian Aid Operations (ECHO) will help the World Health Organization (WHO) boost COVID-19 vaccination campaigns and increase coverage in 15 African countries, where only 15 percent of the population is vaccinated.

The funding is part of the European Union's (EU) humanitarian initiative for COVID-19 vaccination in Africa, which aims to ensure increased access for the most vulnerable and those living in hard-to-reach, remote and conflict-affected areas.

The EU also supports the COVAX Facility, the vaccines part of the Access to COVID-19 Tools Accelerator created to develop and deliver tools to fight the pandemic...

.....

.....

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment

<https://africacdc.org/covid-19-vaccination/>

[Website not responding at inquiry]

.....

.....

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"

<https://sputnikvaccine.com/newsroom/pressreleases/>

Press Releases

Sputnik V becomes the world's first COVID vaccine with proven efficacy for people living with HIV as demonstrated by a joint study between the Gamaleya Center and Moscow City Center for AIDS Prevention and Control published in The Lancet

Press release, 28.03.2022

.....
.....

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare

<https://www.mohfw.gov.in/>

COVID-19 INDIA as on :
02 April 2022, 08:00 IST
(GMT+5:30)

(↑↓ Status change since
yesterday)

Active (0.03%)

13445 (227↓)

Discharged (98.76%)

42492326 (1404↑)

Deaths (1.21%)

521264 (83↑)

COVID-19 Vaccination
as on : 02 April 2022,
08:00 IST (GMT+5:30)

Total Vaccination : 1,84,52,44,856 (18,38,552↑)

Government of India – Press Information Bureau

Latest Press Releases

COVID - 19 Vaccination Update - Day 442

:: India's cumulative vaccination coverage crosses 184.64 Crore

:: More than 11 lakh Vaccine doses administered today till 7 pm

:: More than 1.84 Crore Vaccine Doses administered to 12-14 age group so far

Posted On: 02 APR 2022 8:06PM by PIB Delhi

Indian Council for Medical Research (ICMR)

<https://www.icmr.gov.in/media.html>

Press Releases

No new digest content identified.

.....
.....

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

[We did not identify official announcement about Shanghai confirming the reports below; See China CDC below for additional announcements]

Shanghai separates COVID-positive children from parents in virus fight

By Brenda Goh and Engen Tham

Reuters, April 2, 2022 9:32 AM EDT

Entire Shanghai Placed Under Lockdown

City reported more than 6,300 new Covid infections Friday

Eastern half of city remains under tight restrictions

Bloomberg News. April 1, 2022, 10:43 PM EDT Updated on April 2, 2022, 6:44 AM EDT

Shanghai's 25 million residents are almost all under some form of lockdown as the financial hub struggles to contain the coronavirus's highly contagious omicron variant.

The eastern half of the mega Chinese city remains under tight movement restrictions despite the end of a four-day sweeping lockdown Friday morning, according to a government [statement](#) Saturday. That means the entire population of the metropolis is currently under some form of quarantine as the two-part lockdown [shifted](#) to the western half of Shanghai on Friday.

Residents in the western part of the city, where about two-thirds of its population live, began their four-day lockdown at 3 a.m. local time on Friday as the program approached an end in the east. During the restrictions, residents are barred from leaving home except for mandatory mass Covid tests...

"At present, the epidemic situation is severe and complex, and the task of prevention and control is extremely arduous," Wu Qianyu, an official at the Shanghai municipal health commission, [said](#) at a media briefing...

.....
.....
.....

Emergencies

POLIO

Public Health Emergency of International Concern (PHEIC)

<https://polioeradication.org/polio-today/polio-now/this-week/>

Polio this week as of 30 March 2022

:: On 21 March, the Federal Government of Somalia, World Health Organization (WHO) and members of the Global Polio Eradication Initiative (GPEI) recommitted to stopping the ongoing outbreak of circulating poliovirus type 2 (cVDPV2) in Somalia at a three-day meeting convened in Nairobi, Kenya. Details of the summit are available [here](#).

:: Revised containment guidance (GAPIII) available for public consultation: On [recommendation](#) from the Containment Advisory Group (CAG), and through wide engagement of stakeholders, WHO's Global Action Plan for Poliovirus Containment (GAPIII, 2015) has been revised. Following a period of critical review by the CAG, the document draft is [now available for public consultation](#) until 1 May 2022. Revisions to the guidance have been made based on CAG recommendations, review of relevant bio-risk management documents to determine alignment, scientific evidence and solicited stakeholder comments on various sections. WHO encourages feedback from containment stakeholders. For queries, please email: containment@who.int

Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):

- **DR Congo:** six cVDPV2 cases
- **Egypt:** two cVDPV2 positive environmental samples
- **Nigeria:** three cVDPV2 cases and two positive environmental samples
- **Yemen:** 16 cVDPV2 cases

.....
.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

No new DONs reported.

.....
.....

WHO/OCHA Emergencies

Health emergencies list - WHO

"The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences."

Afghanistan crisis

:: WHO Director-General's opening remarks at the meeting on Interim Priorities for Health Sector in Afghanistan – 29 March 2022

Crisis in Northern Ethiopia *[Last apparent update: 1 June 2021]*

Ebola outbreak, Democratic Republic of the Congo, 2021 *[Last apparent update: 17 Aug 2021]*

Ebola outbreak outbreak, N'Zerekore, Guinea, 2021 *[Last apparent update: 17 Aug 2021]*

Coronavirus disease (COVID-19) pandemic *[See COVID above]*

Ebola outbreak, Equateur Province, Democratic Republic of the Congo, 2020

[Last apparent update: 17 Aug 2021]

Ebola outbreak, North Kivu, Ituri, Democratic Republic of the Congo, 2018 – 2020

[Last apparent update: 17 Aug 2021]

Ebola outbreak, Democratic Republic of the Congo, 2018 *[Last apparent update: 24 July 2018]*

Yemen crisis *[Last apparent update: 12 February 2021]*

Syria crisis *[Last apparent update: 18 June 2021]*

Somalia crisis *[Last apparent update: 24 March 2018]*

Nigeria crisis *[Last apparent update: 1 Oct 2021]*

Ebola outbreak, Democratic Republic of the Congo, 2017 *[Last apparent update: 17 Aug 2021]*

[Zika virus disease outbreak, 2015-2016](#) [Last apparent update: 24 Jan 2020]

[Ebola outbreak: West Africa, 2014-2016](#) [Last apparent update: 17 Aug 2021]

[Iraq crisis](#) [Last apparent update: 9 Jan 2008]

[South Sudan crisis](#) [Last apparent update: 23 Sep 2020]

[Avian influenza A \(H7N9\) virus outbreak](#) [Last apparent update: 13 September 2021]

[Middle East respiratory syndrome \(MERS-CoV\) outbreak](#) [Last apparent update: 8 July 2019]

[Influenza A \(H1N1\) virus, 2009-2010 pandemic](#) [Last apparent update: 10 Aug 2010]

.....

[UN OCHA – Current Emergencies](#)

Current Corporate Emergencies

Afghanistan

No new updates identified.

Northern Ethiopia

Ethiopia - Northern Ethiopia Humanitarian Update Situation Report, 31 March 2022

HIGHLIGHTS

- In Amhara, the regional Government authorities continued with the relocation of internally displaced people.
The number scabies cases in Tigray increased eight-fold from about 400 cases since the start of the year to more than 3,100 cases during the reporting week.
- Partners provided health services to only more than 26,500 people in Tigray during the reporting week. 3.9 million people are estimated to need health care in the region.
- Humanitarian partners reached more than 62,000 people with food assistance in Afar and more than 7,700 people with medical consultations during the reporting week.
- Humanitarian partners reached more than 726,000 people with food assistance in Amhara during the reporting period.

Ukraine

Ukraine: Humanitarian Impact Situation Report (As of 12:00 p.m. (EET) on 1 April 2022)

.....

.....

WHO & Regional Offices [to 02 Apr 2022]

<https://www.who.int/news>

News [Selected]

1 April 2022

Departmental news

[Parliaments promote women's, children's and adolescents' health in the time of COVID-19](#)

31 March 2022

Departmental news

[Letter to malaria partners \(March 2022\)](#)

31 March 2022

Departmental news

[WHO launches guidance on digitally documenting SARS-CoV-2 test results](#)

31 March 2022

News release

[Indian manufacturer new recipient of mRNA technology through the mRNA technology transfer hub](#)

30 March 2022

News release

[Egypt and Nigeria medicines regulators achieve high maturity level in WHO classification and WHO launches list of regulatory authorities that meet international standards](#)

30 March 2022

Departmental news

[WHO urges quality care for women and newborns in critical first weeks after childbirth](#)

30 March 2022

News release

[WHO releases 10-year strategy for genomic surveillance of pathogens](#)

29 March 2022

Departmental news

[European Union funding boosts COVID-19 vaccination in Africa](#)

28 March 2022

Departmental news

[The Netherlands and WHO: Partners for health and human rights around the world](#)

.....

WHO Director General Speeches [selected]

<https://www.who.int/director-general/speeches>

Selected

30 March 2022

Speech

[WHO Director-General's opening remarks at the WHO press conference – 30 March 2022](#)

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region

- :: 29 March 2022 [European Union funding boosts COVID-19 vaccination in Africa](#)
- :: 29 March 2022 [What is impeding Africa's TB fight?](#)
- :: 28 March 2022 [Kenyan lab boosting Africa's genome surveillance](#)

WHO Region of the Americas PAHO

- :: 31 Mar 2022 [New WHO 10-year strategy aims to scale up genomic surveillance](#)

PAHO regional network forms part of worldwide effort to track pathogens Washington, D.C., 31 March 2022 (PAHO) – The World Health Organization (WHO) released a strategy this week to strengthen genomic surveillance around the world. The Pan American Health Organization (PAHO) COVID-19 Genomic Surveillance Regional Network, created at the...

- :: 30 Mar 2022 [WHO urges quality care for women and newborns in critical first weeks after childbirth](#)

New recommendations stress urgency of both physical and mental health support in postnatal period Geneva, 30 March 2022- The World Health Organization (WHO) today launched its first ever global guidelines to support women and newborns in the postnatal period – the first six weeks after birth. This is a critical time for ensuring newborn and...

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

- :: [Battling to protect their patients: how health workers from three Ukrainian hospitals have adapted to working in wartime](#) 01-04-2022
- :: [WHO urges quality care for women and newborns in critical first weeks after childbirth](#) 31-03-2022
- :: [Fighting COVID-19 in prisons: WHO report presents best practices from countries](#) 31-03-2022

WHO Eastern Mediterranean Region EMRO

- :: [Djibouti conducts round two of nationwide polio vaccination campaign](#) 28 March 2022
- :: [Training workshop on medical journalism and countering misinformation concludes in Iraq](#) 28 March 2022
- :: [World TB Day 2022: Getting back on track to diagnose and report TB cases, to save lives](#) 27 March 2022

WHO Western Pacific Region

No new digest content identified.

.....

WHO Events

<https://www.who.int/news-room/events/1>

[Selected]

[Strategic Advisory Group of Experts on Immunization \(SAGE\) - April 2022](#)

4 – 7 April 2022

Public hearings regarding a new international instrument on pandemic preparedness and response

12 – 13 April 2022

In a consensus decision aimed at protecting the world from future infectious diseases crises, in December 2021 the World Health Assembly agreed to kickstart a global process by establishing an

intergovernmental negotiating body (INB) to draft and negotiate a convention, agreement or other international instrument under the Constitution of the World Health Organization to strengthen pandemic prevention, preparedness and response.

Dr Tedros Adhanom Ghebreyesus, WHO Director-General, said the decision by the World Health Assembly was historic in nature, vital in its mission, and represented a once-in-a-generation opportunity to strengthen the global health architecture to protect and promote the well-being of all people.

As part of this historic decision, the World Health Assembly requested the Director-General to hold public hearings, in line with standard WHO practice, to support the work of the INB.

[Registration link not yet available]

.....

New WHO Publications

<https://www.who.int/publications/i>

Selected Titles

31 March 2022

[WHO Guidelines for malaria](#)

31 March 2022

[Digital documentation of COVID-19 certificates: test result: web annex: DDCC:TR core data dictionary...](#)

31 March 2022

[Digital documentation of COVID-19 certificates: test result: technical specifications and implementation...](#)

31 March 2022

[Emergency in Ukraine: external situation report #5, published 31 March 2022: reporting period: 24–30...](#)

30 March 2022

[WHO recommendations on maternal and newborn care for a positive postnatal experience](#)

28 March 2022

[Weekly epidemiological record, 2022, vol. 97, 10 \(full issue\)](#)

28 March 2022

[Global genomic surveillance strategy for pathogens with pandemic and epidemic potential, 2022–2032 \[WHO\]](#)

Overview

The Strategy provides a high-level unifying framework to leverage existing capacities, address barriers and strengthen the use of genomic surveillance in the detection, monitoring and response to public health threats. Genomic surveillance is part of the broader surveillance and laboratory system, and its implementation should reinforce end-to-end capacities including sample collection, diagnostics, data sharing and analysis. The strategy aims to facilitate the connectivity between different disease control programs and surveillance networks. This interoperability will strengthen the cross-cutting essential

public health laboratory functions underpinning genomics holistically. The strategy articulates the overarching goal, objectives and strategic actions needed. These are dependent on commitments from countries, partners and WHO for their implementation.

.....
.....
.....

CDC/ACIP [U.S.] [to 02 Apr 2022]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

Latest News Releases, Announcements [Selected]

[CDC Media Telebriefing: New CDC data illuminate youth mental health threats During the COVID-19 pandemic](#)

Thursday, March 31, 2022

[CDC Recommends Additional Boosters for Certain Individuals](#)

Tuesday, March 29, 2022

... CDC is updating its recommendations to allow certain immunocompromised individuals and people over the age of 50 who received an initial booster dose at least 4 months ago to be eligible for another mRNA booster to increase their protection against severe disease from COVID-19. Separately and in addition, based on [newly published data](#), adults who received a primary vaccine and booster dose of Johnson & Johnson's Janssen COVID-19 vaccine at least 4 months ago may now receive a second booster dose using an mRNA COVID-19 vaccine....

.....

[ACIP Meetings](#)

Next meeting scheduled for June 22-23, 2022

.....

MMWR Weekly: Current Volume (71) April 1, 2022 / No. 13

[PDF of this issuepdf icon](#)

- Universal Hepatitis B Vaccination in Adults Aged 19–59 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022
- Assessment of Epidemiology Capacity in State Health Departments — United States, 2021
- Use of At-Home COVID-19 Tests — United States, August 23, 2021–March 12, 2022
- Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults — VISION Network, 10 States, December 2021–March 2022

.....

[Coronavirus Disease 2019 \(COVID-19\)- CDC](#)

Approximately 25 announcements/reports/data summaries.

:: 3/29/22 Overall US COVID-19 Vaccine Distribution and Administration Update as of Tue, 29 Mar 2022 06:00:00 EST

:: 3/29/22 COVID-19 Vaccine Equity for Racial and Ethnic Minority Groups

...

.....
.....

Africa CDC [to 02 Apr 2022]

<http://www.africacdc.org/>

News

[Website not responding at inquiry]

.....
.....

China CDC

<http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 02 Apr 2022]

<http://en.nhc.gov.cn/>

News

April 2: Daily briefing on novel coronavirus cases in China

On April 1, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 2,129 new cases of confirmed infections.

National Medical Products Administration – PRC [to 02 Apr 2022]

<http://english.nmpa.gov.cn/>

News

Chinese mainland reports 2,086 new local COVID-19 cases

2022-04-02

The Chinese mainland reported 2,086 new locally-transmitted COVID-19 infections on April 1, versus 1,787 a day earlier, the National Health Commission said on April 2.

Chinese mainland reports 1,301 new local COVID-19 cases

2022-03-25

The Chinese mainland on Thursday reported 1,301 locally transmitted COVID-19 cases, down from 2,010 on Wednesday, the National Health Commission said Friday.

Over 88 pct Chinese fully vaccinated against COVID-19: official

2022-04-02

China has fully vaccinated 88.11 percent of its population against COVID-19 as of Thursday, a Chinese health official said Friday.

Nearly 3.27b COVID-19 vaccine doses administered on the Chinese mainland

2022-04-01

Nearly 3.27 billion COVID-19 vaccine doses had been administered on the Chinese mainland as of Wednesday, data from the National Health Commission showed Thursday.

CCDC [Weekly Reports: Current Volume \(4\)](#)

2022-04-01 / No. 13HEALTH MEASUREMENT AND EVALUATION ISSUE

[View PDF of this issue](#)

- [Healthy China: The Future Challenges of Population Health in China: A Projection of the Major Health Problems and Life Expectancy — China, 2015–2050](#)
- [Commentary: Disease Burden: Progresses Made, Current State, Future Challenges, and Opportunities](#)

.....

Contents [[click to move among sections](#)]

:: [Coronavirus \[COVID-19\] - WHO](#)

:: [Emergencies](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

Milestones - Perspectives

.....

Organization Announcements

Editor's Note:

Careful readers will note that the number and range of organizations now monitored in our *Announcements* section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Airfinity [to 02 Apr 2022]

<https://www.airfinity.com/insights>

INSIGHTS & COMPANY NEWS

No new digest content identified.

Paul G. Allen Frontiers Group [to 02 Apr 2022]

<https://alleninstitute.org/news-press/>

News

No new digest content identified.

BMGF - Gates Foundation [to 02 Apr 2022]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

[Qatar Fund for Development and Bill & Melinda Gates Foundation Jointly Pledge up to US\\$200 Million in New Partnership to Help Smallholder Farmers Adapt to Climate Change](#)

Mar 27, 2022

Bill & Melinda Gates Medical Research Institute [to 02 Apr 2022]

<https://www.gatesmri.org/news>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people
No new digest content identified.

CARB-X [to 02 Apr 2022]

<https://carb-x.org/>

News

No new digest content identified.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 02 Apr 2022]

<https://centerforvaccineethicsandpolicy.net/>

News/Analysis/Statements

:: Past weekly editions and posting of all segments of ***Vaccines and Global Health: The Week in Review*** are [available here](#).

:: [Informed Consent: A Monthly Review – April 2022](#) is now posted [here](#)

:: [Statement on ICF \[Informed Consent Form\] Posting for Clinical Trials Involving Gene Editing/Gene Therapies - Invitation to Endorse](#)

:: [Patients, Politics, Pressure :: Pharma Stays Steady \[Mostly\] In Russia Sanctions Context Observations at 30 March 2022](#) David R Curry

CEPI – Coalition for Epidemic Preparedness Innovations [to 02 Apr 2022]

<http://cepi.net/>

Latest News

[The Global Pandemic Preparedness Summit: On the road to 100-Day vaccines](#)

Catch-up on the key highlights from the Summit.

Blog 29 Mar 2022

[Excerpt]

...International policymakers, scientists, and representatives of industry, philanthropy and civil society were united at the Global Pandemic Preparedness Summit—co-hosted in London by the Coalition for Epidemic Preparedness Innovations (CEPI) and the UK Government on March 7-8, 2022—in endorsing the ambition to have safe, effective, and globally accessible vaccines against the next pandemic threat ready in just 100 days.

But the devil will be in the detail in realizing this goal—from raising the US\$3.5 billion required by CEPI to deliver on its pandemic-busting plan over the next five years, to realigning global regulatory systems, to scaling up manufacturing and ensuring supplies of everything down to rubber stoppers for vials....

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 02 Apr 2022]

<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 02 Apr 2022]

<https://dukeghic.org/>

Our Blog

No new digest content identified.

EDCTP [to 02 Apr 2022]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

No new digest content identified.

Emory Vaccine Center [to 02 Apr 2022]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 02 Apr 2022]

<http://www.euvaccine.eu/>

Latest News, Events

No new digest content identified.

Evidence Aid [to 02 Apr 2022]

Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.

<http://www.evidenceaid.org/>

New Resources

[Humanitarian migrant women's experiences of maternity care in Nordic countries Added April 1, 2022](#)

[Cultural competence and awareness of healthcare workers providing care for pregnant migrant women Added March 30, 2022](#)

[Social prescribing for migrants in the United Kingdom Added March 29, 2022](#)

Approaches and frameworks for studying zoonotic diseases and forced migration of people
Added March 28, 2022

Fondation Merieux [to 02 Apr 2022]

<http://www.fondation-merieux.org/>

News, Events

No new digest content identified.

Gavi [to 02 Apr 2022]

<https://www.gavi.org/>

News Releases

No new digest content identified.

GHIT Fund [to 02 Apr 2022]

<https://www.ghitfund.org/newsroom/press>

Press Releases

March 31, 2022

GHIT Fund Announces New Investments: A Total of 740 Million Yen for Malaria Drugs and Vaccine

Global Fund [to 02 Apr 2022]

<https://www.theglobalfund.org/en/news/>

News & Stories

28 March 2022

President Biden Signals a \$6 billion U.S. Pledge for the Seventh Replenishment and Offers to Match \$1 for Every \$2 Contributed by Other Donors

The Global Fund to Fight AIDS, Tuberculosis and Malaria enthusiastically welcomes President Joe Biden's request to the United States Congress for a commitment of US\$2 billion for the Global Fund for fiscal year 2023, the first year of the Global Fund...

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 02 Apr 2022]

<https://www.glopid-r.org/news/>

News

No new digest content identified

Hilleman Laboratories [to 02 Apr 2022]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified

HHMI - Howard Hughes Medical Institute [to 02 Apr 2022]

<https://www.hhmi.org/news>

Press Room

Research Mar 31 2022

[Complete Human Genome Deciphered for the First Time](#)

Twenty years after scientists first reported reading the human genome, the Telomere-to-Telomere consortium has now unveiled a complete version. Their work uncovered hundreds of new genes and opens the door to new insights into evolution and disease.

Research Mar 30 2022

[Discovery of How Hyaluronic Acid Is Made Could Spur New Therapeutics](#)

For over two decades, scientists have puzzled over how vertebrates make the essential polysaccharide hyaluronic acid, which has broad medical applications. One team took a different tack and solved the mystery.

Human Vaccines Project [to 02 Apr 2022]

<http://www.humanvaccinesproject.org/>

News

HVP COVID Report

Apr 01, 2022

[Marc Lipsitch: What Comes Next? Getting Better at Predicting Pandemics](#)

IAVI [to 02 Apr 2022]

<https://www.iavi.org/>

Latest News

No new digest content identified

ICRC [to 02 Apr 2022]

<https://www.icrc.org/en/whats-new>

What's New [Selected]

No new digest content identified

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 02 Apr 2022]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press Releases [Selected]

Launch of ambitious partnership between IFRC and EU: a new model for the humanitarian sector

30/03/2022

Brussels/Geneva, 30 March 2022 - An ambitious partnership between the International Federation of Red Cross and Red Crescent Societies (IFRC) and the Directorate-General for European Civil Protection and Humanitarian Aid Operations (DG ECHO) launched today aims to be a new model for the humanitarian sector.

In response to the increasing number of crises arising worldwide, the pilot Programmatic Partnership "Accelerating Local Action in Humanitarian and Health Crises" aims to support local action in addressing humanitarian and health crises across at least 25 countries with a multi-year EU funding allocation...

Institut Pasteur [to 02 Apr 2022]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified.

IOM / International Organization for Migration [to 02 Apr 2022]

<http://www.iom.int/press-room/press-releases>

News - Selected

News 31 Mar 2022

The People of Afghanistan Must Not be Forgotten: IOM Director General António Vitorino

News 30 Mar 2022

Funding Needed to Assist Over 100,000 Ethiopian Migrants Returning from the Kingdom of Saudi Arabia

News 30 Mar 2022

IOM Appeals for USD 128 Million to Support Rohingya Refugees and Local Communities in Cox's Bazar

News 29 Mar 2022

Number of Venezuelans Crossing the Darien Gap Soars

ISC / International Science Council [to 02 Apr 2022]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

News Blogs Podcasts Events

Blogs

Joint Statement of Intent on the Digital Transformation in the International Scientific and Quality Infrastructure

01.04.2022

The ISC co-signs the Joint Statement of Intent on Digital Transformation in the International Scientific and Quality infrastructure. As the world enters the era of digitalization, it is important to establish a world-wide uniform and secure data exchange format based on the International System of Units.

Blogs

Ukrainian academics face exile, harassment and censorship in ongoing war

31.03.2022

Blogs

What are the principles and structures of science advice?

31.03.2022

The need for science advice in policymaking is on the rise. While the processes by which science advice is provided to governments and within the multilateral system were made apparent during the COVID-19 pandemic, the interest for scientific evidence precedes it. This ISC-INGSA Occasional Paper is intended to explain key structures and processes in a clear and straightforward manner, so the essential elements of science advice are understood.

Blogs

The African Open Science Platform begins to take shape

28.03.2022

The African Open Science Platform (AOSP), which has been hosted by the National Research Foundation (NRF) of South Africa since 2020, aims to position scientists and science systems in Africa at the cutting edge of data-intensive open science. The Platform was first initiated in 2017, and is now ramping up its activities following the appointments of Tshiamo Motshegwa as Director and Nokuthula Mchunu as Deputy-Director.

IVAC [to 02 Apr 2022]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

Webinar: Reaching Zero-dose Children and Supporting Immunization Equity in Humanitarian Contexts

[March 28 : Recording]

IVI [to 02 Apr 2022]

<http://www.ivi.int/>

IVI News & Announcements

IVI, ROK's MOHW expand partnership to promote vaccine development & delivery, bio manufacturing training for LMICs

April 1, 2022, SEOUL, Republic of Korea — The International Vaccine Institute (IVI) and the Ministry of Health and Welfare (MOHW), Republic of Korea, have agreed to strengthen cooperation to promote the development and delivery of vaccines and bio manufacturing workforce training for low- and middle-income countries (LMICs) to help advance global health.

Johns Hopkins Center for Health Security [to 02 Apr 2022]

<https://www.centerforhealthsecurity.org/news/center-news/>

Center News

No new digest content identified.

MSF/Médecins Sans Frontières [to 02 Apr 2022]

<http://www.msf.org/>

Latest [Selected Announcements]

No new digest content identified.

National Academy of Medicine - USA [to 02 Apr 2022]

<https://nam.edu/programs/>

News

No new digest content identified.

National Academy of Sciences - USA [to 02 Apr 2022]

<http://www.nasonline.org/news-and-multimedia/>

News

No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 02 Apr 2022]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No new digest content identified.

NIH [to 02 Apr 2022]

<http://www.nih.gov/news-events/news-releases>

News Releases

[Drug use severity in adolescence affects substance use disorder risk in adulthood](#)

April 1, 2022 — NIH-funded study shows screening for substance use disorder in teens may help predict adult prescription drug use and misuse and prevent overdose.

[NIH experts discuss controlling COVID-19 in commentary on herd immunity](#)

March 31, 2022 — Achieving herd immunity thresholds have been less successful with respiratory viruses which continually mutate. ... DM Morens *et al.* The Concept of Classical Herd Immunity May Not Apply to COVID-19. *The Journal of Infectious Diseases* DOI: [10.1093/infdis/jiac109](https://doi.org/10.1093/infdis/jiac109)([link is external](#)) (2022).

[Researchers generate the first complete, gapless sequence of a human genome](#)

March 31, 2022 — Completion is critical for understanding the full spectrum of human genomic variation and for understanding the genetic contributions to certain diseases.

[See Perspectives above for detail]

NIH begins clinical trial evaluating second COVID-19 booster shots in adults

March 31, 2022 — Study includes multiple variant vaccines.

OECD [to 02 Apr 2022]

<http://www.oecd.org/newsroom/publicationsdocuments/bydate/Newsroom/Library>

New OECD report shows loans to SMEs hit new heights during the pandemic, as small firms face renewed pressures during the recovery

A new OECD report, "Financing SMEs and Entrepreneurs 2022: An OECD Scoreboard" shows that outstanding SME loans increased significantly during the first year of the pandemic. The median stock of SME loans increased by 4.9%, the highest upturn registered since the OECD Scoreboard was created 10 years ago.

PATH [to 02 Apr 2022]

<https://www.path.org/media-center/PressReleases>

Catalytic funding from Bayer Foundation to accelerate digital health entrepreneurship in LMICs

The project aims to create an equitable entrepreneurial environment for digital health developers in the places where PATH works by advancing the broad use of common open-source platforms that speed uptake and ensure sustainability.

Sabin Vaccine Institute [to 02 Apr 2022]

<http://www.sabin.org/updates/pressreleases>
Statements and Press Releases
No new digest content identified.

UNAIDS [to 02 Apr 2022]

<http://www.unaids.org/en>
Selected Press Releases/Reports/Statements
31 March 2022

Helping to break stigma and discrimination against transgender people in Brazil

30 March 2022

"You don't have to be in the military to help—there is military defence, but there is also volunteer work, humanitarian aid is a lot of work"

30 March 2022

Training health-care workers in Indonesia to improve HIV services for young key populations

29 March 2022

Transgender sex workers face frequent abuse

UNHCR Office of the United Nations High Commissioner for Refugees [to 02 Apr 2022]

<http://www.unhcr.org/en-us/media-centre.html>

Selected News Releases, Announcements

Thousands flee into Uganda following clashes in DR Congo

1 Apr 2022

UN High Commissioner for Refugees calls for immediate end to Ukraine war, which has uprooted over 10 million people

31 Mar 2022

UNHCR and partners call for sustained funding and support for Rohingya refugees

29 Mar 2022

UNICEF [to 02 Apr 2022]

<https://www.unicef.org/media/press-releases>

Press Releases, News Notes, Statements [Selected]

Press release

03/30/2022

Two million refugee children flee war in Ukraine in search of safety across borders

<https://www.unicef.org/press-releases/two-million-refugee-children-flee-war-ukraine-search-safety-across-borders>

NEW YORK/GENEVA/KYIV, 30 March 2022 – Two million children have now been forced to flee Ukraine, as the war rages on. “The situation inside Ukraine is spiralling,” said UNICEF Executive Director Catherine Russell. “As the number of children fleeing their homes continues to climb, we must remember that every single one of them needs protection,...

Statement

03/29/2022

Less than half of countries are implementing learning recovery strategies at scale to help children catch up

<https://www.unicef.org/press-releases/less-half-countries-are-implementing-learning-recovery-strategies-scale-help>

NEW YORK/PARIS/WASHINGTON D.C., 30 March 2022 - “More than two years into the COVID-19 pandemic, we are witnessing a colossal loss to children’s learning. Less than half of countries are implementing learning recovery strategies at scale to help children catch up. Unless all countries implement and expand programmes in the coming months, they risk...

Press release

03/29/2022

With 23 countries yet to fully reopen schools, education risks becoming ‘greatest divider’ as COVID-19 pandemic enters third year

<https://www.unicef.org/press-releases/23-countries-yet-fully-reopen-schools-education-risks-becoming-greatest-divider>

NEW YORK, 30 March 2022 – As the COVID-19 pandemic enters its third year, 23 countries – home to around 405 million schoolchildren – are yet to fully open schools, with many schoolchildren at risk of

dropping out, according to a new UNICEF report released today. Are children really learning? features country-level data on the impact of the COVID-...

Unitaid [to 02 Apr 2022]

<https://unitaid.org/>

Featured News

No new digest content identified.

Vaccine Equity Cooperative [nee Initiative] [to 02 Apr 2022]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 02 Apr 2022]

<https://www.vaccineacceptance.org/>

Announcements, Blog

No new digest content identified.

Vaccine Confidence Project [to 02 Apr 2022]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 02 Apr 2022]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

No new digest content identified.

Wellcome Trust [to 02 Apr 2022]

<https://wellcome.ac.uk/news>

News. Opinion, Reports

No new digest content identified.

The Wistar Institute [to 02 Apr 2022]

<https://www.wistar.org/news/press-releases>

Press Releases

No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 02 Apr 2022]

<https://www.wfpha.org/>

Latest News - Blog
No new digest content identified.

World Bank [to 02 Apr 2022]

<http://www.worldbank.org/en/news/all>

Selected News, Announcements

South Sudan Receives \$200 Million to Strengthen Health Systems and Accelerate COVID-19 Vaccination

JUBA, March 31, 2022—Today the World Bank approved \$200 million in additional financing to support South Sudan's continued efforts to improve its capacity to respond to COVID-19. This International Development...

Date: March 31, 2022 Type: Press Release

Less than half of countries are implementing learning recovery strategies at scale to help children catch up

Statement by UNESCO Assistant Director-General for Education Stefania Giannini; UNICEF Director of Education Robert Jenkins; World Bank Global Director for Education Jaime Saavedra NEW YORK/PARIS/WASHINGTON...

Date: March 30, 2022 Type: Press Release

Covid-19 and femicides in Brazil - The impact of social distancing measures, financial constraints, and mitigating policies

Nearly two years after the onset of the Covid-19 pandemic, gender-based violence (GBV) continues to be an ongoing challenge for countries. Following early evidence of increased risks of GBV in the first...

Date: March 30, 2022 Type: Publication

Addressing the Impact of COVID-19 on Gender-Based Violence: An Ongoing Challenge for 2022

Date: March 30, 2022 Type: Infographic

Banco Mundial aportará US\$100 millones para apoyar los esfuerzos de vacunación contra la COVID-19 en Panamá

Additional Financing for the Panama COVID-19 Emergency Response will enable access to vaccines and help ensure effective vaccine deployment. WASHINGTON, D.C., March 28, 2022 – The World Bank approved today...

Date: March 28, 2022 Type: Press Release

World Customs Organization – WCO [to 02 Apr 2022]

<http://www.wcoomd.org/>

Latest News

30 March 2022

WCO and WTO launch a joint publication on Customs use of advanced technologies

29 March – The WCO and the World Trade Organization (WTO) held a webinar to launch their joint publication on Customs use of advance technologies. The event attracted more than 700 attendees and provided insights into how advanced technologies can help Customs administrations facilitate the flow of goods across borders. The publication titled, "The role of advanced technologies in cross-border

trade: A customs perspective” provides the current state of play and sheds light on the opportunities and challenges Customs face when deploying these technologies.

:: The full publication can be accessed [here](#).

:: The recording of the webinar is available [here](#).

World Organisation for Animal Health (OIE) [to 02 Apr 2022]

<https://www.oie.int/en/media/news/>

Press Releases, Statements

No new digest content identified.

WTO - World Trade Organisation [to 02 Apr 2022]

http://www.wto.org/english/news_e/news_e.htm

WTO News and Events [Selected]

WTO issues inventory of COVID-19 information resources

30 March 2022

The WTO has published a compilation of information resources, such as databases and reports, that provide information and data on a wide range of issues relating to COVID-19. The inventory provides a useful tool for government officials and other stakeholders wishing to access information about the latest developments regarding COVID-19.

.....

ARM [Alliance for Regenerative Medicine] [to 02 Apr 2022]

<https://alliancerm.org/press-releases/>

Selected Press Releases

Cell and Gene Therapies Poised to Disrupt Health Care Status Quo with Wave of New Treatments

March 31, 2022 Washington, DC

The Alliance for Regenerative Medicine, the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, today released its 2021 Annual Report, showcasing a year of significant advances and forecasting continued growth ahead.

BIO [to 02 Apr 2022]

<https://www.bio.org/press-releases>

Press Releases, Letters, Testimony, Comments [Selected]

No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 02 Apr 2022]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 02 Apr 2022]

<https://internationalbiotech.org/news/>

News

No new digest content identified.

IFPMA [to 02 Apr 2022]

<http://www.ifpma.org/resources/news-releases/>

Selected Press Releases, Statements, Publications

No new digest content identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest content identified.

International Alliance of Patients' Organizations – IAPO [to 02 Apr 2022]

<https://www.iapo.org.uk/news/topic/6>

Press and media [Selected]

No new digest content identified.

PhRMA [to 02 Apr 2022]

<http://www.phrma.org/>

Latest News [Selected]

No new digest content identified.

*

*

*

*

Contents [click to move among sections]

:: Coronavirus [COVID-19] - WHO

:: Emergencies

:: Organization Announcements

:: Journal Watch

Milestones - Perspectives

*

*

*

*

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 13, 2022 Issue 1

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 24, Number 4: E249-341 Apr 2022

<https://journalofethics.ama-assn.org/issue/health-equity-us-latinx-communities>

Health Equity in US Latinx Communities

Latinx communities in the US include over 60 million people with a plurality of political beliefs, cultural practices, and wealth. This diversity is also expressed in population health data: some health indicators suggest advantages of Latinx community membership while other data demonstrate inequitable disease burden and maldistribution of environmental and occupational risk. Legacies of colonial conquest of the Americas persist in discrimination and marginalization today and are embodied by members of our Latinx communities.

American Journal of Infection Control

April 2022 Volume 50 Issue 4 p367-476

<http://www.ajicjournal.org/current>

Major Articles

[Influenza vaccination of home health care staff and the impact on patient hospitalizations](#)

Jingjing Shang, Jordan M. Harrison, Ashley M. Chastain,...Elizabeth A. Madigan, Monika Pogorzelska-Maziarz, Andrew W. Dick

Published in issue: April 2022

p369-374

Global Perspective Article

[Global analysis of the COVID-19 research landscape and scientific impact](#)

Ying Chen, Shixiang Chen, Bingxin Ma,...Qi Lu, Yaogang Wang, Yue Zhao

Published online: January 02, 2022

p446-453

American Journal of Preventive Medicine

April 2022 Volume 62 Issue 4 p473-660

<https://www.ajpmonline.org/current>

Research Articles

Racial and Ethnic Disparities in COVID-19 Vaccination Coverage: The Contribution of Socioeconomic and Demographic Factors

Austin M. Williams, Heather B. Clayton, James A. Singleton

Published online: November 17, 2021

p473-482

Modeling COVID-19 Mortality Across 44 Countries: Face Covering May Reduce Deaths

Sahar Motallebi, Rex C.Y. Cheung, Babak Mohit, Shahram Shahabi, Amir Alishahi Tabriz, Syamak Moattari

Published online: November 10, 2021

p483-491

Missed Vaccination Opportunities Among U.S. Adolescents by Area Characteristics

Sandi L. Pruitt, Jasmin A. Tiro, Deanna Kepka, Kevin Henry

Published online: February 03, 2022

p538-547

Research Briefs

Racial/Ethnic Variation in Veterans Health Administration COVID-19 Vaccine Uptake

Taona P. Haderlein, Michelle S. Wong, Kenneth T. Jones, Ernest M. Moy, Anita H. Yuan, Donna L. Washington

Published online: October 20, 2021

p596-601

American Journal of Public Health

April 2022 112(52)

<http://ajph.aphapublications.org/toc/ajph/current>

Supplement 2 2022 = Global Opioid Crisis

American Journal of Tropical Medicine and Hygiene

Volume 106 (2022): Issue 2 (Feb 2022)

<https://www.ajtmh.org/view/journals/tpmd/106/2/tpmd.106.issue-2.xml>

[Reviewed earlier]

Annals of Internal Medicine

March 2022 Volume 175, Issue 3

<http://annals.org/aim/issue>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 305 April 2022

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/305/suppl/C>

Editorial No access

[AI Journal Special Issue on Ethics for Autonomous Systems](#)

Michael Fisher, Sven Koenig, Marija Slavkovik

Article 103677

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 02 Apr 2022)

[No new digest content identified]

BMJ Global Health

March 2022 - Volume 7 - 3

<https://gh.bmj.com/content/7/3>

[Reviewed earlier]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 02 Apr 2022)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 02 Apr 2022)

[An assessment of Veterans attitudes and willingness to receiving the COVID-19 vaccine: a mixed methods study](#)

While several safe and effective COVID-19 vaccines have been available since December 2020, many eligible individuals choose to remain unvaccinated. This vaccine hesitancy is an important factor affecting our ...

Authors: Jessica Gardner, Gabriel Brown, Jadisha Vargas-Correa, Frances Weaver, Israel Rubinstein and Howard S. Gordon

Citation: BMC Infectious Diseases 2022 22:308

Content type: Research article Published on: 29 March 2022

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 02 Apr 2022)

[Collection and use of human materials during TB clinical research; a review of practices](#)

Human biological materials are usually stored for possible future use in research because they preserve valuable biological information, save time and resources, which would have been spent on collection of fr...

Authors: Joseph Ochieng, Betty Kwagala and Nelson Sewankambo

Citation: BMC Medical Ethics 2022 23:36

Content type: Research Published on: 29 March 2022

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 02 Apr 2022)

[AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2](#)

Binding and neutralising anti-Spike antibodies play a key role in immune defence against SARS-CoV-2 infection. Since it is known that antibodies wane with time and new immune-evasive variants are emerging, we ...

Authors: Marah G. Chibwana, Thandeka Moyo-Gwete, Gaurav Kwatra, Jonathan Mandolo, Tandile Hermanaus, Thopisang Motlou, Nonkululeko Mzindle, Frances Ayres, Mphatso Chaponda, Godwin Tembo, Percy Mwenechanya, Ndaona Mitole, Chisomo Jassi, Raphael Kamng'ona, Louise Afran, David Mzinza...

Citation: BMC Medicine 2022 20:128

Content type: Research article Published on: 28 March 2022

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 02 Apr 2022)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 02 Apr 2022)

[Clustering of countries according to the COVID-19 incidence and mortality rates](#)

Two years after the beginning of the COVID-19 pandemic on December 29, 2021, there have been 281,808,270 confirmed cases of COVID-19, including 5,411,759 deaths. This information belongs to almost 216 Countries...

Authors: Kimiya Gohari, Anoshirvan Kazemnejad, Ali Sheidaei and Sarah Hajari

Citation: BMC Public Health 2022 22:632

Content type: Research Published on: 1 April 2022

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 02 Apr 2022)

[No new digest content identified]

BMJ Evidence-Based Medicine

April 2022 - Volume 27 - 2

<https://ebm.bmj.com/content/27/2>

[Reviewed earlier]

BMJ Open

March 2022 - Volume 12 - 3
<https://bmjopen.bmj.com/content/12/3>
[Reviewed earlier]

Bulletin of the World Health Organization

Volume 100(2); 2022 Mar 1
<https://www.ncbi.nlm.nih.gov/pmc/issues/399608/>
[Reviewed earlier]

Cell

Mar 31, 2022 Volume 185 Issue 7 p1105-1260
<https://www.cell.com/cell/current>

Articles

[Virome characterization of game animals in China reveals a spectrum of emerging pathogens](#)

Wan-Ting He, et al.

An analysis of 18 different wildlife species traded or consumed as food across China identifies nearly 100 mammalian-infecting viruses, of which a subset has the potential to jump between species and cause respiratory diseases.

Child Care, Health and Development

Volume 48, Issue 2, Pages: 177-357 March 2022
<https://onlinelibrary.wiley.com/toc/13652214/current>
[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 111, Issue 4 Pages: 705-971 April 2022
<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

Therapeutic Innovations in Neuroscience

The theme of this issue of *Clinical Pharmacology & Therapeutics* (CPT) encompasses neuroscience in the broad sense to include neurology and psychiatry, nonclinical and clinical aspects, novel clinical trial methodologies, and modeling and simulation approaches applicable to central nervous system (CNS) drug development and therapy. While naturally the last two years have been dominated by coronavirus disease 2019 (COVID-19), it is important not to forget that drug development for other indications has not been stopped, albeit many trials were affected in terms of delays in recruitment and collection of clinical data.

Clinical Therapeutics

February 2022 Volume 44 Issue 2 p155-348
<http://www.clinicaltherapeutics.com/current>

Contemporary Report

[Consolidated Health Economic Evaluation Reporting Standards 2022 \(CHEERS 2022\) Statement: Updated Reporting Guidance for Health Economic Evaluations](#)

Don Husereau, Michael Drummond, Federico Augustovski,...Raoh-Fang Pwu, Sophie Staniszewska
on behalf of CHEERS 2022 ISPOR Good Research Practices Task Force
Published online: February 12, 2022

Reviews

Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA

Sarah Mofid, Winona Rei Bolislis, Thomas C. Kühler

Published online: January 21, 2022

p306-322

Open Access

Clinical Trials

Volume 19 Issue 1, February 2022

<https://journals.sagepub.com/toc/ctja/19/1>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 02 Apr 2022]

Identifying transferable lessons from cholera epidemic responses by Médecins Sans Frontières in Mozambique, Malawi and the Democratic Republic of Congo, 2015–2018: a scoping review

Authors: Lauren D'Mello-Guyett, Oliver Cumming, Elliot Rogers, Rob D'hondt, Estifanos Mengitsu, Maria Mashako, Rafael Van den Bergh, Placide Okitayemba Welo, Peter Maes and Francesco Checchi

Content type: Research 29 March 2022

Contemporary Clinical Trials

Volume 114 March 2022

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/114/suppl/C>

[Reviewed earlier]

The CRISPR Journal

Volume 5, Issue 1 / February 2022

<https://www.liebertpub.com/toc/crispr/5/1>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 9, issue 4, December 2021

<https://link.springer.com/journal/40142/volumes-and-issues/9-4>

[Reviewed earlier]

Current Opinion in Infectious Diseases

April 2022 - Volume 35 - Issue 2

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

Volume 108, Issue 1 December 2020

<https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current>

[Reviewed earlier]

Developing World Bioethics

Volume 22, Issue 1 Pages: 1-62 March 2022

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 32, Issue 1, 2021

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 15 - Issue 6 - December 2021

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 46, Issue 2 Pages: 299-586 April 2022

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

EMBO Reports

Volume 23 Issue 3 3 March 2022

<https://www.embopress.org/toc/14693178/current>

[New issue; No digest content identified]

Emerging Infectious Diseases

Volume 28, Number 2—February 2022

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

Epidemics

Volume 38 March 2022

<https://www.sciencedirect.com/journal/epidemics/vol/38/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 150 - 2022

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 44, Issue 2 Pages: 1-40 March–April 2022

<https://onlinelibrary.wiley.com/toc/25782363/current>

Consent and decisional capacity; Outside experts and IRBs; Therapeutic misconception

[Reviewed earlier]

Ethics & International Affairs

Winter 2021 (35.4) | December 2021

<https://www.ethicsandinternationalaffairs.org/2021/winter-2021-35-4/>

TABLE OF CONTENTS

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 20 February 2022

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/20/suppl/C>

[Reviewed earlier]

The European Journal of Public Health

Volume 32, Issue 2, April 2022

<https://academic.oup.com/eurpub/issue/32/2>

Health services research

[Health care provider trust in vaccination: a systematic review and qualitative meta-synthesis](#)

Mobeen Ahmad, Adebisi Akande, Umair Majid

European Journal of Public Health, Volume 32, Issue 2, April 2022, Pages 207–213,

<https://doi.org/10.1093/eurpub/ckab209>

COVID-19

[Socioeconomic and demographic risk factors in COVID-19 hospitalization among immigrants and ethnic minorities](#)

Sabrina Islamoska, Jørgen Holm Petersen, Thomas Benfield, Marie Norredam

European Journal of Public Health, Volume 32, Issue 2, April 2022, Pages 302–310,

<https://doi.org/10.1093/eurpub/ckab186>

Primary COVID-19 vaccine cycle and booster doses efficacy: analysis of Italian nationwide vaccination campaign

Camilla Mattiuzzi, Giuseppe Lippi

European Journal of Public Health, Volume 32, Issue 2, April 2022, Pages 328–330,

<https://doi.org/10.1093/eurpub/ckab220>

Expert Review of Vaccines

Vol 21 (4) 2022

<https://www.tandfonline.com/toc/ierv20/current>

Editorial

Vaccination strategies between compulsion and incentives. The Italian Green Pass experience

Pasquale Stefanizzi, Francesco Paolo Bianchi, Nazario Brescia, Davide Ferorelli & Silvio Tafuri

Pages: 423-425

Published online: 13 Jan 2022

Editorial

Inequitable COVID-19 vaccine distribution and the intellectual property rights prolong the pandemic

Emrah Altindis

Pages: 427-430

Published online: 27 Jan 2022

Review

COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies

Manuela Di Fusco, Jay Lin, Shailja Vaghela, Melissa Lingohr-Smith, Jennifer L. Nguyen, Thomas Scassellati Sforzolini, Jennifer Judy, Alejandro Cane & Mary M. Moran

Pages: 435-451

Published online: 03 Feb 2022

The next major emergent infectious disease: reflections on vaccine emergency development strategies

Yu Bai, Qian Wang, Mingchen Liu, Lianlian Bian, Jianyang Liu, Fan Gao, Qunying Mao, Zhongfang Wang, Xing Wu, Miao Xu & Zhenglun Liang

Pages: 471-481

Published online: 26 Jan 2022

Original Research

Article

Parental COVID-19 vaccine hesitancy: a cross-sectional survey in Italy

Aida Bianco, Giorgia Della Polla, Silvia Angelillo, Concetta P Pelullo, Francesca Licata & Italo F. Angelillo

Pages: 541-547

Published online: 02 Jan 2022

Article

COVID-19 vaccine acceptance and hesitancy among healthcare workers in South Africa

Charles S Wiysonge, Samuel M Alobwede, Patrick de Marie C Katoto, Elvis B Kidzeru, Evelyn N Lumngwena, Sara Cooper, Rene Goliath, Amanda Jackson & Muki S Shey

Pages: 549-559

Published online: 06 Jan 2022

Forum for Development Studies

Volume 49, 2022 - Issue 1

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 02 Apr 2022]

[No new digest content identified]

Global Health Action

Volume 15, Issue 1 (2022)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 10, No. 1 February 28, 2022

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

[Accessed 02 Apr 2022]

[No new digest content identified]

Global Public Health

Volume 17, Issue 4 (2022)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 02 Apr 2022]

[No new digest content identified]

Health and Human Rights

Volume 23, Issue 2, December 2021

<https://www.hhrjournal.org/volume-23-issue-2-december-2021/>

[Reviewed earlier]

Health Economics, Policy and Law

Volume 17 - Issue 2 - April 2022

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 37, Issue 3, March 2022

<https://academic.oup.com/heapol/issue/37/3>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 02 Apr 2022]

Human Gene Therapy

Volume 33, Issue 5-6 / March 2022

<https://www.liebertpub.com/toc/hum/33/5-6>

[Reviewed earlier]

Humanitarian Practice Network

<https://odihpn.org/>

Online Article

[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 18, Issue 1, 2022

<https://www.tandfonline.com/toc/khvi20/current>

Article

[**Attitudes of hospital physicians toward childhood mandatory vaccines in France: A cross-sectional survey**](#)

Pierre Verger, Christian Dualé, Dimitri Scronias, Nezha Lenzi, Céline Pulcini & Odile Launay

Article: 1870393

Published online: 22 Feb 2021

Review

Established and new rotavirus vaccines: a comprehensive review for healthcare professionals

Volker Vetter, Robert C. Gardner, Serge Debrus, Bernd Benninghoff & Priya Pereira

Article: 1870395

Published online: 19 Feb 2021

Article

Influence of social media on parents' attitudes towards vaccine administration

Khalid A Al-Regaiey, Wjdan S Alshamry, Reem A Alqarni, Majd K Albarrak, Rinad M Alghoraiby, Danah Y Alkadi, Leen R Alhakeem, Shahid Bashir & Muhammad Iqbal

Article: 1872340

Published online: 17 Feb 2021

Article

Re-thinking yellow fever vaccines: fighting old foes with new generation vaccines

Gerardo Montalvo Zurbia-Flores, Christine S Rollier & Arturo Reyes-Sandoval

Article: 1895644

Published online: 11 May 2021

Article Commentary

Key ethical considerations to guide the adjudication of a single-dose HPV vaccine schedule

Ruha Shadab, James V. Lavery, SarahAnn M. McFadden, Jad A. Elharake, Fauzia Malik & Saad B. Omer

Article: 1917231

Published online: 19 May 2021

Article

The efficacy of human papillomavirus vaccination in young Japanese girls: the interim results of the OCEAN study

Kosuke Hiramatsu, Yutaka Ueda, Asami Yagi, Akiko Morimoto, Tomomi Egawa-Takata, Satoshi Nakagawa, Eiji Kobayashi, Toshihiro Kimura, Tadashi Kimura, Ryoko Minekawa, Yumiko Hori, Kazuaki Sato, Eiichi Morii, Tomio Nakayama, Yoshimichi Tanaka, Yoshito Terai, Masahide Ohmichi, Tomoyuki Ichimura, Toshiyuki Sumi, Hiromi Murata, Hidetaka Okada, Hidekatsu Nakai, Noriomi Matsumura, Masaki Mandai, Jyunko Saito, Yorihiro Horikoshi, Tetsu Takagi, Takayuki Enomoto & Kentaro Shimura

Article: 1951098

Published online: 22 Nov 2021

Article

Tracking the impact of the COVID-19 pandemic on routine infant vaccinations in the Dominican Republic

Manuel Colomé-Hidalgo, Juan Donado Campos & Ángel Gil de Miguel

Article: 1972708

Published online: 13 Oct 2021

Article Commentary

Addressing an urgent global public health need: Strategies to recover routine vaccination during the COVID-19 pandemic

Anna Larson, Ava Skolnik, Alexandra Bhatti & Rachel Mitrovich

Article: 1975453

Published online: 21 Oct 2021

Article Commentary

[Addressing an urgent global public health need: Strategies to recover routine vaccination during the COVID-19 pandemic](#)

Anna Larson, Ava Skolnik, Alexandra Bhatti & Rachel Mitrovich

Article: 1975453

Published online: 21 Oct 2021

Article

[A scoping review of global vaccine certificate solutions for COVID-19](#)

Salima S. Mithani, A. Brianne Bota, David T. Zhu & Kumanan Wilson

Pages: 1-12

Published online: 06 Oct 2021

[Gaps in knowledge about the vaccine coverage of immunocompromised children: a scoping review](#)

Shannon E. MacDonald, Airlie Palichuk, Linda Slater, Hailey Tripp, Laura Reifferscheid & Catherine Burton

Pages: 1-16

Published online: 16 Jul 2021

Immunity

Mar 08, 2022 Volume 55 Issue 3 p377-574

<https://www.cell.com/immunity/current>

[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 02 Apr 2022]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content>

[Accessed 02 Apr 2022]

[How to improve the COVID-19 health education strategy in impoverished regions: a pilot study](#)

Authors: Huimin Wang, Rujun Liao, Xin Chen, Jie Yu, Tianyu Zhu, Qiang Liao and Tao Zhang

Content type: Research Article 29 March 2022

International Health

Volume 14, Issue 2, March 2022

<https://academic.oup.com/inthealth/issue/14/2>

[Reviewed earlier]

International Human Rights Law Review

Volume 10 (2021): Issue 2 (Dec 2021)

<https://brill.com/view/journals/hrlr/10/2/hrlr.10.issue-2.xml>

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol 9, No 1 (2022) January 2022

<https://www.ijcmph.com/index.php/ijcmph/issue/view/84>

[Reviewed earlier]

International Journal of Epidemiology

Volume 51, Issue 1, February 2022

<https://academic.oup.com/ije/issue>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 14 Issue 5 2021

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/14/iss/5>

Table of Contents

[Reviewed earlier]

JAMA

March 22/29, 2022, Vol 327, No. 12, Pages 1109-1194

<https://jamanetwork.com/journals/jama/currentissue>

[Reviewed earlier]

JAMA Network

[COVID-19 Update April 2, 2022](#)

These articles on COVID-19 were published across the JAMA Network in the last week.

JAMA Pediatrics

March 2022, Vol 176, No. 3, Pages 220-332

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

JBIR Evidence Synthesis

March 2022 - Volume 20 - Issue 3

<https://journals.lww.com/jbisr/Pages/currenttoc.aspx>

[New issue; No digest content identified]

Journal of Adolescent Health

April 2022 Volume 70 Issue 4 p517-696

<https://www.jahonline.org/current>

Commentaries

COVID-19 Vaccination in Children: Lessons Learned From Human Papillomavirus Vaccination

Lisa N. Mansfield, Lilanthi Balasuriya, Arleen Brown

Published online: January 18, 2022

p525-527

Original Articles

Parents' Willingness to Vaccinate Their Children With COVID-19 Vaccine: Results of a Survey in Italy

Gabriella Di Giuseppe, Concetta Paola Pelullo, Andrea Salvatore Volgare, Francesco Napolitano, Maria Pavia

Published online: January 17, 2022

Influence of Perceived Adolescent Vaccination Desire on Parent Decision for Adolescent COVID-19 Vaccination

Jeanne R. Delgado, Peter G. Szilagyi, Jennifer Brazier Peralta,...Sitaram Vangala, Rashmi Shetgiri, Arie Kapteyn

Published online: January 18, 2022

p567-570

Journal of Artificial Intelligence Research

Vol. 73 (2022)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

Journal of Community Health

Volume 47, issue 2, April 2022

<https://link.springer.com/journal/10900/volumes-and-issues/47-2>

[Reviewed earlier]

Journal of Development Economics

Volume 156 May 2022

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/156/suppl/C>

[New issue; No digest content identified]

Journal of Empirical Research on Human Research Ethics

Volume 17 Issue 1-2, February-April 2022

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

March 2022 - Volume 76 - 3

<https://jech.bmj.com/content/76/3>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 14, Issue 4 Pages: 257-345 December 2021

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 17, Issue 3, 2021

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 33, Number 1, February 2022

<https://muse.jhu.edu/issue/47329>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 24, issue 2, April 2022

<https://link.springer.com/journal/10903/volumes-and-issues/24-2>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 20, 2022 _ Issue 1

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of Infectious Diseases

Volume 225, Issue 3, 1 February 2022

<https://academic.oup.com/jid/issue/225/3>

EDITORIAL COMMENTARY

[Widespread Use of Varicella Vaccine Does Not Reduce Immunity to Zoster of Others](#)

Anne A Gershon, Michael D Gershon

The Journal of Infectious Diseases, Volume 225, Issue 3, 1 February 2022, Pages 361–363,

<https://doi.org/10.1093/infdis/jiab501>

COVID-2019

Infants Younger Than 6 Months Infected With SARS-CoV-2 Show the Highest Respiratory Viral Loads

Valeria Ochoa, Fernando Erra Díaz, Ezequiel Ramirez, María Clara Fentini, Mauricio Carobene ...
The Journal of Infectious Diseases, Volume 225, Issue 3, 1 February 2022, Pages 392–395,
<https://doi.org/10.1093/infdis/jiab577>

VACCINES

Editor's Choice

No Consistent Evidence of Decreased Exposure to Varicella-Zoster Virus Among Older Adults in Countries with Universal Varicella Vaccination

Stephane Carryn, Brigitte Cheuvart, Michael Povey, Alemnew F Dagnaw, Rafael Harpaz ...
The Journal of Infectious Diseases, Volume 225, Issue 3, 1 February 2022, Pages 413–421,
<https://doi.org/10.1093/infdis/jiab500>

By repurposing humoral and cell-mediated immunogenicity data from a large multinational trial enrolling adults aged ≥ 50 years, we found no consistent evidence of differences in varicella-zoster virus exposure between countries with widely circulating varicella versus countries with universal vaccination.

Effectiveness of Human Papillomavirus (HPV) Vaccination Against Penile HPV Infection in Men Who Have Sex With Men and Transgender Women

Rachel L Winer, John Lin, Troy D Querec, Elizabeth R Unger, Joshua E Stern ...
The Journal of Infectious Diseases, Volume 225, Issue 3, 1 February 2022, Pages 422–430,
<https://doi.org/10.1093/infdis/jiab390>

Penile quadrivalent human papillomavirus (HPV) vaccine–type HPV prevalence was lower among young men who have sex with men (MSM) self-reporting HPV vaccination at age ≤ 18 years than among MSM with no or unknown vaccination. Results suggest that HPV vaccination is effective against penile HPV infections when administered to MSM aged ≤ 18 years.

Universal Infant Hepatitis B Virus (HBV) Vaccination for 35 Years: Moving Toward the Eradication of HBV

Kai-Chi Chang, Mei-Hwei Chang, Huey-Ling Chen, Jia-Feng Wu, Chin-Hao Chang ...
The Journal of Infectious Diseases, Volume 225, Issue 3, 1 February 2022, Pages 431–435,
<https://doi.org/10.1093/infdis/jiab401>

Universal hepatitis B virus (HBV) vaccination effectively prevented chronic HBV infection. High vaccination coverage, comprehensive screening, and antiviral agents for pregnant mothers are essential to eliminate its perinatal transmission and for future elimination.

Journal of Medical Ethics

April 2022 - Volume 48 - 4

<http://jme.bmj.com/content/current>

Original research

Pandemic prioritarianism (4 February, 2021) Free

Lasse Nielsen

Ethics of vaccine refusal (26 February, 2021)

Michael Kowalik

Taking the burden off: a study of the quality of ethics consultation in the time of COVID-19

(2 April, 2021) Free

Lulia Kana, Andrew Shuman, Raymond De Vries, Janice Firn

Vaccine confidence, public understanding and probity: time for a shift in focus? (9 March, 2021)

Ana Wheelock, Jonathan Ives

Journal of Patient-Centered Research and Reviews

Volume 9, Issue 1 (2022)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

Journal of Pediatrics

March 2022 Volume 24 2p1-266

<http://www.jpeds.com/current>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

<https://joppp.biomedcentral.com/>

[Accessed 02 Apr 2022]

Redistribution of critical drugs in shortage during the first wave of COVID-19 in France: from operating theaters to intensive care units

Tension in the supply of highly consumed drugs for patients with COVID-19 (propofol, midazolam, curares) led the French government to set up a centralized supply of hospitals with distribution based on the num...

Authors: Claire Chapuis, Rémy Collomp, Laura Albaladejo, Hugo Terrisse, Stéphane Honoré, Jean-Luc Bosson, Pierrick Bedouch and Pierre Albaladejo

Citation: Journal of Pharmaceutical Policy and Practice 2022 15:28

Content type: Research Published on: 1 April 2022

Assessing public knowledge, attitudes and determinants of third COVID-19 vaccine booster dose acceptance: current scenario and future perspectives

People with weakened immune systems may not develop adequate protection after taking two doses of the mRNA-combined COVID-19 vaccine. The additional dose may improve the level of protection against Covid-19.

Authors: Ammar Abdulrahman Jairoun, Sabaa Saleh Al-Hemyari, Faris El-Dahiyat, Maimona Jairoun, Moyad Shahwan, Mena Al Ani, Mustafa Habeb and Zaheer-Ud-Din Babar

Citation: Journal of Pharmaceutical Policy and Practice 2022 15:26

Content type: Research Published on: 28 March 2022

Why COVID vaccines for young children (5–11 years) are not essential at this moment in time?

The Joint Committee on Vaccination and Immunisation (JCVI) in UK has recently advised that COVID vaccines in 5–11-year-old children is non-essential. This has created an outrage among some healthcare professio...

Authors: Hamid A. Merchant

Citation: Journal of Pharmaceutical Policy and Practice 2022 15:25

Content type: Commentary Published on: 28 March 2022

Journal of Public Health Management & Practice

May/June 2022 - Volume 28 - Issue 3

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[New issue; No digest content identified]

Journal of Public Health Policy

Volume 43, issue 1, March 2022

<https://link.springer.com/journal/41271/volumes-and-issues/43-1>

[Reviewed earlier]

Journal of Refugee & Global Health

Volume 4, Issue 1 (2021)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

Journal of the Royal Society – Interface

March 2022 Volume 19 Issue 188

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 29, Issue 2, March 2022

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

Journal of Virology

Volume 96 Number 4 February 2022

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

Apr 02, 2022 Volume 399 Number 10332 p1279-1358, e20-e29

<https://www.thelancet.com/journals/lancet/issue/current>

Articles

Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study

Tommy Nyberg, et al. COVID-19 Genomics UK (COG-UK) consortium,
Open Access

Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India

Akash Khobragade, et al. on behalf of the ZyCoV-D phase 3 Study Investigator Group

The Lancet Child & Adolescent Health

Apr 2022 Volume 6 Number 4 p215-278, e13-e15

<https://www.thelancet.com/journals/lanchi/issue/current>

Editorial

A roadmap of recovery for the COVID generation

The Lancet Child & Adolescent Health

... The pandemic has had wide-ranging and long-lasting effects on young people, but children's developmental plasticity and resilience give us room for optimism. As the world moves into the next phase of pandemic recovery and living with COVID-19, we must grasp this opportunity to support every child to catch up and thrive. *The Lancet Child & Adolescent Health* will be publishing a Commission to build a roadmap of recovery for this COVID generation. We call for collaborators and research from all aspects of child and adolescent health—particularly from our colleagues in development, social science, and adolescent health—to join us.

Comment

Assessing the impact of the pandemic in children and adolescents: SARS-CoV-2 infection and beyond

Erika Molteni, Michael Absoud, Emma L Duncan

Articles

Global, regional, and national minimum estimates of children affected by COVID-19-associated orphanhood and caregiver death, by age and family circumstance up to Oct 31, 2021: an updated modelling study

H Juliette T Unwin, et al.

Open Access

Lancet Digital Health

Apr 2022 Volume 4 Number 4 e207-e289

<https://www.thelancet.com/journals/landig/issue/current>

[New issue; No digest content identified]

Lancet Global Health

Apr 2022 Volume 10 Number 4 e448-e584

<https://www.thelancet.com/journals/langlo/issue/current>

Articles

Residual risk of mother-to-child transmission of hepatitis B virus infection despite timely birth-dose vaccination in Cameroon (ANRS 12303): a single-centre, longitudinal observational study

Yusuke Shimakawa, et al.

Viewpoint

COVID-19 vaccine dose sparing: strategies to improve vaccine equity and pandemic preparedness

Geert V T Roozen, et al.

Strengthening global health security by improving disease surveillance in remote rural areas of low-income and middle-income countries

Katherine E L Worsley-Tonks, et al.

Lancet Infectious Diseases

Apr 2022 Volume 22 Number 4p 427-562, e101-e127
<https://www.thelancet.com/journals/laninf/issue/current>

Articles

All-cause mortality during the COVID-19 pandemic in Chennai, India: an observational study

Joseph A Lewnard, et al.

Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses

Ramachandran Thiruvengadam, et al. on behalf of the Department of Biotechnology India Consortium for COVID-19 research

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials

Gang Zeng, et al.

Mass drug administration of ivermectin and dihydroartemisinin–piperaquine against malaria in settings with high coverage of standard control interventions: a cluster-randomised controlled trial in The Gambia

Edgard D Dabira, et al.

Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial

Ganesh Kumar Rai, et al.

Review

A clinical case definition of post-COVID-19 condition by a Delphi consensus

Joan B Soriano, et al. on behalf of the WHO Clinical Case Definition Working Group on Post-COVID-19 Condition

[Accelerating research and development of new vaccines against tuberculosis: a global roadmap](#)

Frank Cobelens, et al. on behalf of the TB Vaccine Roadmap Stakeholder Group

Lancet Public Health

Apr 2022 Volume 7 Number 4 e291-e390

<https://www.thelancet.com/journals/lanpub/issue/current>

Articles

[Effectiveness of nationwide programmatic testing and treatment for latent tuberculosis infection in migrants in England: a retrospective, population-based cohort study](#)

Luis C Berrocal-Almanza, et al

[Maintaining face mask use before and after achieving different COVID-19 vaccination coverage levels: a modelling study](#)

Sarah M Bartsch, et al.

[COVID-19 vaccine coverage and factors associated with vaccine uptake among 23 247 adults with a recent history of homelessness in Ontario, Canada: a population-based cohort study](#)

Salimah Z Shariff, et al.

Lancet Respiratory Medicine

Apr 2022 Volume 10 Number 4 p313-420, e34-e43

<https://www.thelancet.com/journals/lanres/issue/current>

Articles

[SARS-CoV-2 infection and vaccine effectiveness in England \(REACT-1\): a series of cross-sectional random community surveys](#)

Marc Chadeau-Hyam, et al. in collaboration with the COVID-19 Genomics UK consortium

Open Access

[Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged \$\geq 65\$ years: a phase 2, randomised, open-label study](#)

Ruvim Izikson, et al.

Maternal and Child Health Journal

Volume 26, issue 3, March 2022

<https://link.springer.com/journal/10995/volumes-and-issues/26-3>

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 42 Issue 3, April 2022

<http://mdm.sagepub.com/content/current>

[New issue; No digest content identified]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 100, Issue 1 Pages: 1-313 March 2022

<https://onlinelibrary.wiley.com/toc/14680009/current>

[New issue; No digest content identified]

Nature

Volume 603 Issue 7903, 31 March 2022

<https://www.nature.com/nature/volumes/603/issues/7903>

Editorial | 29 March 2022

[Time is running out for COVID vaccine patent waivers](#)

The European Union needs to go further and faster in embracing a temporary waiver on COVID-19 intellectual property.

Comment | 28 March 2022

[Global vaccination must be swifter](#)

Speeding up development of new vaccines won't help much in the next pandemic, unless world leaders work faster to roll out vaccination globally.

Thomas J. Bollyky, Jennifer Nuzzo, Emily Pond

Nature Biotechnology

Volume 40 Issue 3, March 2022

<https://www.nature.com/nbt/volumes/40/issues/3>

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 02 Apr 2022)

[No new digest content identified]

Nature Genetics

Volume 54 Issue 3, March 2022

<https://www.nature.com/ng/volumes/54/issues/3>

[Reviewed earlier]

Nature Human Behaviour

Volume 6 Issue 3, March 2022

<https://www.nature.com/nathumbehav/volumes/6/issues/3>

[Reviewed earlier]

Nature Medicine

Volume 28 Issue 3, March 2022

<https://www.nature.com/nm/volumes/28/issues/3>

[Reviewed earlier]

Nature Reviews Genetics

Volume 23 Issue 3, March 2022

<https://www.nature.com/nrg/volumes/23/issues/3>

[Reviewed earlier]

Nature Reviews Immunology

Volume 22 Issue 3, March 2022

<https://www.nature.com/nri/volumes/22/issues/3>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 21 Issue 3, March 2022

<https://www.nature.com/nrd/volumes/21/issues/3>

[Reviewed earlier]

New England Journal of Medicine

March 31, 2022 Vol. 386 No. 13

<https://www.nejm.org/toc/nejm/medical-journal>

Original Articles

[**Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection**](#)

V. Hall and Others

[**Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19**](#)

A. Hammerman and Others

[**Higher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria**](#)

N.N. Chamma-Siqueira and Others

Editorials

[**Added Benefit of Covid-19 Vaccination after Previous Infection**](#)

N.P. Klein

[**Audio Interview: Effectiveness of Covid-19 Vaccination in Children**](#)

E.J. Rubin, L.R. Baden, and S. Morrissey

njp Vaccines

<https://www.nature.com/njpvaccines/>

[Accessed 02 Apr 2022]

[No new digest content identified]

Pediatrics

Volume 149, Issue 4, April 1, 2022

<https://pediatrics.aappublications.org/>

Articles

Youth Well-being During the COVID-19 Pandemic

Courtney K. Blackwell, PhD; Maxwell Mansolf, PhD; Phillip Sherlock, PhD; Jody Ganiban, PhD; Julie A. Hofheimer, PhD ...

Severity of Acute COVID-19 in Children <18 Years Old March 2020 to December 2021

Christopher B. Forrest, MD, PhD; Evanette K. Burrows, MPH; Asuncion Mejias, MD, PhD; Hanieh Razzaghi, MPH; Dimitri Christakis, MD, MPH ...

Safety of Live Attenuated Influenza Vaccine in Children With Asthma

Andrew G. Sokolow, MD; Amy P. Stallings, MD; Carolyn Kercsmar, MD; Theresa Harrington, MD, MPH; Natalia Jimenez-Truque, PhD, MSCI ...

Advocacy Case Study

Vaccination for Justice-Involved Youth

Paula N. Goldman, MD; Nicholas Szoko, MD; Laura Lynch, PA; Jacquelin Rankine, MD, MS

Quality Reports

Improving Pneumococcal Vaccination Rates in High-risk Children in Specialty Clinics

Julia G. Harris, MD; Luke A. Harris, MBA; Liset Olarte, MD; E. Claire Elson, PharmD; Rachel Moran, BA

PharmacoEconomics

Volume 40, issue 3, March 2022

<https://link.springer.com/journal/40273/volumes-and-issues/40-3>

[Reviewed earlier]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 02 Apr 2022)

Responsible handling of ethics in data publication

Daniella Lowenberg, Iratxe Puebla

Perspective | published 28 Mar 2022 PLOS Biology

<https://doi.org/10.1371/journal.pbio.3001606>

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 02 Apr 2022)

[No new digest content identified]

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 02 Apr 2022)

[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 02 Apr 2022)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 02 Apr 2022]

Research Article

[COVID-19 prevention behaviors, trust, and intent to vaccinate among youth at risk for HIV](#)

Joan Christodoulou, Anne E. Fehrenbacher, Elizabeth H. Shaw, Eleanor M. Vincent, Jessica L. Saleska

Research Article | published 31 Mar 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0266321>

[COVID-19 vaccine hesitancy among marginalized populations in the U.S. and Canada: Protocol for a scoping review](#)

Peter A. Newman, Luke Reid, Suchon Tepjan, Sophia Fantus, Kate Allan, Thabani Nyoni, Adrian Guta, Charmaine C. Williams

Study Protocol | published 31 Mar 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0266120>

[Communication about vaccine efficacy and COVID-19 vaccine choice: Evidence from a survey experiment in the United States](#)

Sarah Kreps, Douglas L. Kriner

Research Article | published 30 Mar 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0265011>

[Association between statewide financial incentive programs and COVID-19 vaccination rates](#)

Harsha Thirumurthy, Katherine L. Milkman, Kevin G. Volpp, Alison M. Buttenheim, Devin G. Pope

Research Article | published 30 Mar 2022 PLOS ONE

<https://doi.org/10.1371/journal.pone.0263425>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 02 Apr 2022]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

March 22, 2022 | vol. 119 | no. 12

<https://www.pnas.org/toc/pnas/119/12>

[New issue; No digest content identified]

March 15, 2022 | vol. 119 | no. 11

<https://www.pnas.org/toc/pnas/119/11>

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[New issue; No digest content identified]

Prehospital & Disaster Medicine

Volume 37 - Issue 2 - April 2022

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[New issue; No digest content identified]

Preventive Medicine

Volume 157 April 2022

<https://www.sciencedirect.com/journal/preventive-medicine/vol/157/suppl/C>

Review article Full text access

[**Willingness, refusal and influential factors of parents to vaccinate their children against the COVID-19: A systematic review and meta-analysis**](#)

Petros Galanis, Irene Vraika, Olga Siskou, Olympia Konstantakopoulou, ... Daphne Kaitelidou

Article 106994

Research article Full text access

[**Generational differences in beliefs about COVID-19 vaccines**](#)

Vivian Hsing-Chun Wang, Diana Silver, José A. Pagán

Article 107005

Proceedings of the Royal Society B

30 March 2022 Volume 289 Issue 1971

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

Public Health

Volume 204 Pages 1-86 (March 2022)

<https://www.sciencedirect.com/journal/public-health/vol/204/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 14, Issue 3, November 2021

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Reports

Volume 137 Issue 2, March/April 2022

<https://journals.sagepub.com/toc/phrg/137/2>

[Reviewed earlier]

Qualitative Health Research

Volume 32 Issue 4, March 2022

<https://journals.sagepub.com/toc/qhra/current>

[Reviewed earlier]

Research Ethics

Volume 18 Issue 2, April 2022

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 02 Apr 2022]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Selected Articles

30 Mar 2022

[Corruption and its relation to prevalence and death due to noncommunicable diseases and risk factors: a global perspective](#)

Original research | English |

Risk Analysis

Volume 42, Issue 2 February 2022

<https://onlinelibrary.wiley.com/toc/15396924/current>

Special Issue: Uncertainty in Risk Analysis: Bridging Science, Management and Communication

[New issue; No digest content identified]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 02 Apr 2022]

[No new digest content identified]

Science

Volume 376| Issue 6588| 1 Apr 2022

<https://www.science.org/toc/science/current>

Special issue - Completing the human genome

Introduction to Special Issue

Filling the gaps

BY Laura M. Zahn

31 Mar 2022: 42-43

A fully sequenced human genome was triumphantly announced more than 20 years ago. However, owing to technological limitations, some genomic regions remained unresolved. Here, Science presents research by the Telomere-to-Telomere (T2T) Consortium, reporting on the endeavor to complete a comprehensive human reference genome. Generated primarily by long-read sequencing of a hydatidiform mole, a doubly haploid growth, this effort adds ~200 megabases of genetic information—a full chromosome's worth—to the human genome.

Through the resolution of previously unsequenceable and unalignable regions, mostly composed of highly repetitive sequences, this reference genome allows for a detailed characterization of the centromeric satellite repeats, transposable elements, and segmental duplications. Mapping of genomic sequences, including those from previously published studies, resolves aspects of human genetic diversity, including evolutionary comparisons with our primate relatives. Furthermore, it allows for identification of how changes in methylation density differ within and among centromeres and how epigenetics can affect the transcription of repeat sequences.

These investigations have only begun to tease apart how the T2T reference genome influences the detection of biomedically relevant variants and the evolution of genomic regions that determine human traits. Although much remains to be discovered, the T2T reference genome provides another celebratory benchmark to observe as we continue to delve into the genetics that underlie our complete selves.

The complete sequence of a human genome

BY Sergey Nurk et al [89 authors]

31 Mar 2022: 44-53

Abstract

Since its initial release in 2000, the human reference genome has covered only the euchromatic fraction of the genome, leaving important heterochromatic regions unfinished. Addressing the remaining 8% of the genome, the Telomere-to-Telomere (T2T) Consortium presents a complete 3.055 billion-base pair sequence of a human genome, T2T-CHM13, that includes gapless assemblies for all chromosomes except Y, corrects errors in the prior references, and introduces nearly 200 million base pairs of sequence containing 1956 gene predictions, 99 of which are predicted to be protein coding. The completed regions include all centromeric satellite arrays, recent segmental duplications, and the short arms of all five acrocentric chromosomes, unlocking these complex regions of the genome to variational and functional studies.

Science Translational Medicine

Volume 14| Issue 638| 30 Mar 2022
<https://www.science.org/toc/stm/current>

Viewpoint

[The trillion dollar vaccine gap](#)

BY Simone Pecetta...Rino Rappuoli

30 Mar 2022

Global public investment and a renewed focus on vaccine economics are necessary to prevent new pandemics and grant equitable vaccine access worldwide.

Abstract

New technologies and unprecedented public investment have transformed vaccine development and allowed fast delivery of safe and efficacious COVID-19 vaccines, mitigating the impact of the pandemic on health and the economy. A quantum change in public ...

Social Science & Medicine

Volume 294 February 2022

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/294/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 02 Apr 2022]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 42, issue 3-4, August 2021

<https://link.springer.com/journal/11017/volumes-and-issues/42-3>

Special Issue: A plea for an experimental philosophy of medicine

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 46 March–April 2022

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/46/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 27, Issue 3 Pages: i-iv, 217-336 March 2022

<https://onlinelibrary.wiley.com/toc/13653156/current>

RESEARCH ARTICLES

[Reviewed earlier]

Vaccine

Volume 40, Issue 11, Pages 1513-1680 (8 March 2022)

<https://www.sciencedirect.com/journal/vaccine/vol/40/issue/11>

Optimmunize: Improving the Beneficial Effects of Vaccines

Editorial Full text access

Introduction

Eleanor N. Fish, Christine S. Benn, Sabra L. Klein

There is increasing evidence that vaccines, in addition to their disease-specific effects, have important off-target or non-specific effects (NSEs). A number of major observations with significant implications for child survival have been identified ([Table 1](#)).

Epidemiological studies have consistently found differential effects of live and non-live vaccines on overall mortality. Live vaccines have beneficial NSEs. Non-live vaccines may increase mortality, particularly for females, in spite of their pathogen-specific disease-protective effects. Many studies have focused on Bacillus Calmette-Guérin (BCG), where BCG has been shown to have beneficial NSEs in both animal and human challenge studies. Notably, different strains of BCG have different NSEs.

A growing number of studies have shown that vaccines may induce epigenetic changes, which can reprogram the innate immune system. Some vaccines will induce innate immune training, leading to an increased immune response to subsequent unrelated pathogens. Others may lead to innate immune tolerance, thereby rendering the recipient less likely to respond appropriately to subsequent unrelated challenges.

In February 2020, the 1st Optimmunize Conference was held at the Wellcome Genome Campus in Hinxton, near Cambridge, UK. The aim of the conference was to bring together epidemiologists, clinicians and immunologists to discuss and explore the underlying immunologic and genetic bases of NSEs, how generalizable they are, whether they can prove useful in geriatric and veterinary medicine, and why the NSEs often differ between sexes. This Special Issue provides a selection of the papers arising from the Conference....

Value in Health

April 2022 Volume 25 Issue 4 p473-676

<https://www.valueinhealthjournal.com/current>

[New issue; No digest content identified]

.....
.....

Pre-Print Servers

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

Research Article metrics

Revised

[Integration of HIV prevention and sexual and reproductive health in the era of anti-retroviral-based prevention: findings from assessments in Kenya, Malawi and Zimbabwe](#)

[version 2; peer review: 3 approved with reservations]

Fannie Kachale, Imelda Mahaka, Fatima Mhuriro, Mary Mugambi, Joseph Murungu, Barbra Ncube, Getrude Ncube, Albert Ndwiga, Rose Nyirenda, Violet Otindo, Anna Carter, Megan Dunbar, Janet Fleischman, Jessica Rodrigues, Kate Segal

Peer Reviewers Morkor Newman Owiredi; Daniel K. Were; Rose Patricia Oluoch

Funder

Bill and Melinda Gates Foundation

LATEST VERSION PUBLISHED 28 Mar 2022

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints - complete but unpublished manuscripts - that describe human health research conducted, analyzed, and interpreted according to scientific principles...

[COVID-19 vaccination coverage by company size and the effects of socioeconomic factors and workplace vaccination in Japan: a cohort study](#)

Koji Mori, Takahiro Mori, Tomohisa Nagata, Hajime Ando, Ayako Hino, Seiichiro Tateishi, Mayumi Tsuji, Keiji Muramatsu

medRxiv 2022.03.30.22273203; doi: <https://doi.org/10.1101/2022.03.30.22273203>

[Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine \(GBP510\) adjuvanted with AS03: a phase 1/2, randomized, placebo-controlled, observer-blinded trial](#)

Joon Young Song, Won Suk Choi, Jung Yeon Heo, Jin Soo Lee, Dong Sik Jung, Shin-Woo Kim, Kyung Hwa Park, Joong Sik Eom, Su Jin Jeong, Jacob Lee, Ki Tae Kwon, Hee Jung Choi, Jang Wook Sohn, Young Keun Kim, Ji Yun Noh, Woo Joo Kim, François Roman, Maria Angeles Ceregado, Francesca Solmi, Agathe Philippot, Alexandra C. Walls, Lauren Carter, David Veessler, Neil King, Hun Kim, Ji Hwa Ryu, Su Jeon Lee, Yong Wook Park, Ho keun Park, Hee Jin Cheong

medRxiv 2022.03.30.22273143; doi: <https://doi.org/10.1101/2022.03.30.22273143>

[Immunogenicity of Pfizer-BioNTech COVID-19 mRNA Primary Vaccination Series in Recovered Individuals Depends on Symptoms at Initial Infection.](#)

Sabryna Nantel, Benoit Bourdin, Kelsey Adams, Julie Carbonneau, Henintsoa Rabezanaha, Marie-Eve Hamelin, Deirdre McCormack, Patrice Savard, Yves Longtin, Matthew Cheng, Gaston DeSerres, Jacques Corbeil, Vladimir Gilca, Mariana Baz, Guy Boivin, Caroline Quach, Helene Decaluwe

medRxiv 2022.03.29.22272714; doi: <https://doi.org/10.1101/2022.03.29.22272714>

[Effect of vaccination rates on the prevalence and mortality of COVID-19](#)

Jacob Westerhout, Hamid Khataee, Zoltan Neufeld

medRxiv 2022.03.31.22273274; doi: <https://doi.org/10.1101/2022.03.31.22273274>

[Uptake of COVID-19 vaccines among pregnant women: a systematic review and meta-analysis](#)

Petros A Galanis, Irene Vraka, Olga Siskou, Olympia Konstantakopoulou, Aglaia Katsiroumpa, Daphne Kaitelidou

medRxiv 2022.04.01.22273296; doi: <https://doi.org/10.1101/2022.04.01.22273296>

Interpretation of non-responders to SARS-CoV-2 vaccines using WHO International Standard

Qiang Zeng, Xue Yang, Qi Gao, Biao-yang Lin, Yong-zhe Li, Gang Huang, Yang Xu

medRxiv 2022.03.31.22273272; doi: <https://doi.org/10.1101/2022.03.31.22273272>

Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation: test negative case-control study

Julia Stowe, Nick Andrews, Freja Kirsebom, Mary Ramsay, Jamie Lopez Bernal

medRxiv 2022.04.01.22273281; doi: <https://doi.org/10.1101/2022.04.01.22273281>

Remdesivir for the treatment of hospitalised patients with COVID-19: final results from the DisCoVeRy randomised, controlled, open-label trial

Florence Ader, Maude Bouscambert-Duchamp, Maya Hites, Nathan Peiffer-Smadja, Julien Poissy, Drifa Belhadi, Alpha Diallo, Christelle Delmas, Juliette Saillard, Aline Dechanet, Claire Fougerou, Minh-Patrick Lê, Gilles Peytavin, Noémie Mercier, Priyanka Velou, Sarah Tubiana, Xavier Lescure, Emmanuel Faure, Saad Nseir, Jean-Christophe Richard, Florent Wallet, François Goehringer, Benjamin Lefèvre, Antoine Kimmoun, François Raffi, Benjamin Gaborit, Jean Reignier, Jean-Philippe Lanoix, Claire Andrejak, Yoann Zerbib, Firouzé Bani-Sadr, Bruno Mourvilliers, François Danion, Yvon Ruch, Raphaël Clere-Jehl, Vincent Le Moing, Kada Klouche, Karine Lacombe, Guillaume Martin-Blondel, Fanny Vardon-Bounes, André Cabié, Jean-Marie Turmel, Lionel Piroth, Mathieu Blot, Élisabeth Botelho-Nevers, Amandine Gagneux-Brunon, Guillaume Thiery, François Bénézit, Rostane Gaci, Joy Mootien, Sébastien Gallien, Denis Garot, Kevin Bouiller, Loïc Epelboin, Stéphane Jauréguiberry, Alexandre Gaymard, Gil Verschelden, Sandra Braz, Joao Miguel Ferreira Ribeiro, Michael Joannidis, Thérèse Staub, Antoine Altdorfer, Richard Greil, Alexander Egle, Jérémie Guedj, Marion Noret, Roberto Roncon-Albuquerque, Jose-Artur Paiva, Bruno Lina, Dominique Costagliola, Yazdan Yazdanpanah, Charles Burdet, France Mentré

medRxiv 2022.03.30.22273206; doi: <https://doi.org/10.1101/2022.03.30.22273206>

Effectiveness of Typhoid Conjugate Vaccine in Zimbabwe used in response to an outbreak among children and young adults: a matched case control study

Maria S. Lightowler, Portia Manangazira, Fabienne Nackers, Michel Van Herp, Isaac Phiri, Kuziwa

Kuwenyi, Isabella Panunzi, Daniela Garone, Farayi Marume, Andrew Tarupiwa, Eva Ferreras, Clemence Duri, Francisco J. Luquero

medRxiv 2022.03.28.22273032; doi: <https://doi.org/10.1101/2022.03.28.22273032>

Reducing societal impacts of SARS-CoV-2 interventions through subnational implementation

Mark M. Dekker, Luc E. Coffeng, Frank P. Pijpers, Debabrata Panja, Sake J. de Vlas

medRxiv 2022.03.31.22273222; doi: <https://doi.org/10.1101/2022.03.31.22273222>

Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative

Guillaume Butler-Laporte, Gundula Povysil, Jack Kosmicki, Elizabeth T Cirulli, Theodore Drivas, Simone Furini, Chadi Saad, Axel Schmidt, Pawel Olszewski, Urszula Korotko, Mathieu Quinodoz, Elifnaz Çelik, Kousik Kundu, Klaudia Walter, Junghyung Jung, Amy D Stockwell, Laura G Sloofman, Alexander W

Charney, Daniel Jordan, Noam Beckmann, Bartłomiej Przychodzen, Timothy Chang, Tess D Pottinger, Ning Shang, Fabian Brand, Francesca Fava, Francesca Mari, Karolina Chwialkowska, Magdalena Niemira, Szymon Pula, J Kenneth Baillie, Alex Stuckey, Andrea Ganna, Konrad J Karczewski, Kumar Veerapen, Mathieu Bourgey, Guillaume Bourque, Robert JM Eveleigh, Vincenzo Forgetta, David Morrison, David Langlais, Mark Lathrop, Vincent Mooser, Tomoko Nakanishi, Robert Frithiof, Michael Hultström, Miklos Lipcsey, Yanara Marincevic-Zuniga, Jessica Nordlund, Kelly M. Schiabor Barrett, William Lee, Alexandre Bolze, Simon White, Stephen Riffle, Francisco Tanudjaja, Efren Sandoval, Iva Neveux, Shaun Dabe, Nicolas Casadei, Susanne Motameny, Manal Alaamery, Salam Massadeh, Nora Aljawini, Mansour S. Almutairi, Yaseen M. Arabi, Saleh A. Alqahtan, Fawz S. Al Harthi, Amal Almutairi, Fatima Alqubaishi, Sarah Alotaibi, Albandari Binowayn, Ebtehal A. Alsolm, Hadeel El Bardisy, Mohammad Fawzy, COVID-19 Host Genetics Initiative, DeCOI Host Genetics Group, GEN-COVID Multicenter Study, GenOMICC Consortium, Japan COVID-19 Task Force, Regeneron Genetics Center, Daniel H Geschwind, Stephanie Arteaga, Alexis Stephens, Manish J. Butte, Paul C. Boutros, Takafumi N. Yamaguchi, Shu Tao, Stefan Eng, Timothy Sanders, Paul J. Tung, Michael E. Broudy, Yu Pan, Alfredo Gonzalez, Nikhil Chavan, Ruth Johnson, Bogdan Pasaniuc, Brian Yaspan, Sandra Smieszek, Carlo Rivolta, Stephanie Bibert, Pierre-Yves Bochud, Maciej Dabrowski, Pawel Zawadzki, Mateusz Sypniewski, Elżbieta Kaja, Pajaree Chariyavilaskul, Voraphoj Nilaratanakul, Nattiya Hirankarn, Vorasuk Shotelersuk, Monnat Pongpanich, Chureerat Phokaew, Wanna Chetruengchai, Yosuke Kawai, Takanori Hasegawa, Tatsuhiko Naito, Ho Namkoong, Ryuya Eda, Akinori Kimura, Seishi Ogawa, Takanori Kanai, Koichi Fukunaga, Yukinori Okada, Seiya Imoto, Satoru Miyano, Serghei Mangul, Malak S Abedalthagafi, Hugo Zeberg, Joseph J Grzymalski, Nicole L Washington, Stephan Ossowski, Kerstin U Ludwig, Eva C Schulte, Olaf Riess, Marcin Moniuszko, Mirosław Kwasniewski, Hamdi Mbarek, Said I Ismail, Anurag Verma, David B Goldstein, Krzysztof Kiryluk, Alessandra Renieri, Manuel Ferreira, J Brent Richards
medRxiv 2022.03.28.22273040; doi: <https://doi.org/10.1101/2022.03.28.22273040> Revision

Emerging Therapies for COVID-19: the value of information from more clinical trials

Stijntje W. Dijk, Eline Krijkamp, Natalia Kunst, Cary P. Gross, John B. Wong, M.G. Myriam Hunink
medRxiv 2022.03.29.22273041; doi: <https://doi.org/10.1101/2022.03.29.22273041>

Persistent health issues, adverse events of significant concern, and effectiveness of COVID-19 vaccination- findings from a real-world cohort study of healthcare workers in north India

Upinder Kaur, Sapna Bala, Aditi Joshi, Noti Taruni Srija Reddy, Chetan, Mayank Chauhan, Nikitha Pedapanga, Shubham Kumar, Anurup Mukherjee, Vaibhav Mishra, Dolly Talda, Rohit Singh, Rohit Kumar Gupta, Ashish Kumar Yadav, Poonam Jyoti Rana, Jyoti Srivastava, Shobha Bhat K, Anup Singh, Naveen Kumar PG, Manoj Pandey, Kishor Patwardhan, Sangeeta Kansal, Sankha Shubhra Chakrabarti
medRxiv 2022.03.26.22272613; doi: <https://doi.org/10.1101/2022.03.26.22272613>

Nationwide Effectiveness of First and Second SARS-CoV2 Booster Vaccines during the Delta and Omicron Pandemic Waves in Hungary (HUN-VE 2 Study)

Zoltán Kiss, István Wittmann, Lőrinc Polivka, György Surján, Orsolya Surján, Zsófia Barcza, Gergő Attila Molnár, Dávid Nagy, Veronika Müller, Krisztina Bogos, Péter Nagy, István Kenessey, András Wéber, Mihály Pálosi, János Szilávik, Zsuzsa Schaff, Zoltán Szekanecz, Cecília Müller, Miklós Kásler, Zoltán Vokó
medRxiv 2022.03.27.22273000; doi: <https://doi.org/10.1101/2022.03.27.22273000>

Impact of the Russian invasion of Ukraine on the COVID-19 pandemic dynamics

Igor Nesteruk
medRxiv 2022.03.26.22272979; doi: <https://doi.org/10.1101/2022.03.26.22272979>

Genomic epidemiology reveals the impact of national and international restrictions measures on the SARS-CoV-2 epidemic in Brazil

Marta Giovanetti, Svetoslav Nanev Slavov, Vagner Fonseca, Eduan Wilkinson, Houriiyah Tegally, José Salvatore Leister Patané, Vincent Louis Viala, James Emmanuel San, Evandra Strazza Rodrigues, Elaine Vieira Santos, Flavia Aburjaile, Joilson Xavier, Hegger Fritsch, Talita Emile Ribeiro Adelino, Felicidade Pereira, Arabela Leal, Felipe Campos de Melo Iani, Glauco de Carvalho Pereira, Cynthia Vazquez, Gladys Mercedes Estigarribia Sanabria, Elaine Cristina de Oliveira, Luiz Demarchi, Julio Croda, Rafael dos Santos Bezerra, Loyze Paola Oliveira de Lima, Antonio Jorge Martins, Claudia Renata dos Santos Barros, Elaine Cristina Marqueze, Jardelina de Souza Todao Bernardino, Debora Botequio Moretti, Ricardo Augusto Brassaloti, Raquel de Lello Rocha Campos Cassano, Pilar Drummond Sampaio Corrêa Mariani, João Paulo Kitajima, Bibiana Santos, Rodrigo Proto-Siqueira, Vlademir Vicente Cantarelli, Stephane Tosta, Vanessa Brandão Nardy, Luciana Reboredo de Oliveira da Silva, Marcela Kelly Astete Gómez, Jaqueline Gomes Lima, Adriana Aparecida Ribeiro, Natália Rocha Guimarães, Luiz Takao Watanabe, Luana Barbosa Da Silva, Raquel da Silva Ferreira, Mara Patricia F. da Penha, María José Ortega, Andrea Gómez de la Fuente, Shirley Villalba, Juan Torales, María Liz Gamarra, Carolina Aquino, Gloria Patricia Martínez Figueredo, Wellington Santos Fava, Ana Rita C. Motta-Castro, James Venturini, Sandra Maria do Vale Leone de Oliveira, Crhistinne Cavalheiro Maymone Gonçalves, Maria do Carmo Debur Rossa, Guilherme Nardi Becker, Mayra Marinho Presibella, Nelson Quallio Marques, Irina Nastassja Riediger, Sonia Raboni, Gabriela Mattoso Coelho, Allan Henrique Depieri Cataneo, Camila Zanluca, Claudia N Duarte dos Santos, Patricia Akemi Assato, Felipe Allan da Silva da Costa, Mirele Daiana Poleti, Jessika Cristina Chagas Lesbon, Elisangela Chicaroni Mattos, Cecilia Artico Banho, Livia Sacchetto, Marília Mazzi Moraes, Rejane Maria Tommasini Grotto, Jayme A. Souza-Neto, Maurício Lacerda Nogueira, Heidge Fukumasu, Luiz Lehmann Coutinho, Rodrigo Tocantins Calado, Raul Machado Neto, Ana Maria Bispo de Filippis, Rivaldo Venancio da Cunha, Carla Freitas, Cassio Roberto Leonel Peterka, Cássia de Fátima Rangel Fernandes, Wildo Navegantes de Araújo, Rodrigo Fabiano do Carmo Said, Maria Almiron, Carlos Frederico Campelo de Albuquerque e Melo, José Lourenço, Tulio de Oliveira, Edward C. Holmes, Ricardo Haddad, Sandra Coccuzzo Sampaio, Maria Carolina Elias, Simone Kashima, Luiz Carlos Junior de Alcantara, Dimas Tadeu Covas
medRxiv 2021.10.07.21264644; doi: <https://doi.org/10.1101/2021.10.07.21264644> Revision

Inconsistent directions of change in case severity across successive SARS-CoV-2 variant waves suggests an unpredictable future

David J. Pascall, Elen Vink, Guy Mollett, Rachel Blacow, Naomi Bulteel, Robyn Campbell, Alasdair Campbell, Sarah Clifford, Chris Davis, Ana da Silva Filipe, Ludmila Fjodorova, Ruth Forrest, Emily Goldstein, Rory Gunson, John Haughney, Matthew T.G. Holden, Patrick Honour, Joseph Hughes, Edward James, Tim Lewis, Martin McHugh, Yusuke Onishi, Ben Parcell, David L. Robertson, Noha El Sakka, Sharif Shabaan, James G. Shepherd, Katherine Smollett, Kate Templeton, Elizabeth Wastnedge, Thomas Williams, Tommy Nyberg, Shaun R. Seaman, Oscar MacLean, Craig Wilkie, Surajit Ray, The COVID-19 Genomics UK (COG-UK) consortium, Emma C. Thomson
medRxiv 2022.03.24.22272915; doi: <https://doi.org/10.1101/2022.03.24.22272915>

Wellcome Open Research [to 02 Apr 2022]
<https://wellcomeopenresearch.org/browse/articles>
[Accessed 02 Apr 2022]

Wellcome Open Research provides all Wellcome researchers with a place to rapidly publish any results they think are worth sharing. All articles benefit from rapid publication, transparent peer review and editorial guidance on making all source data openly available.

Research Article metrics

Revised

[The construction of rare disease discourse on YouTube: highlighting a disparity between policy rhetoric and patient practices around public engagement](#) [version 2; peer review: 1 approved with reservations]

Matthew Hanchard

Peer Reviewer Narelle Warren

Funder

Wellcome

LATEST VERSION PUBLISHED 01 Apr 2022

Method Article metrics

Revised

[Methodology of Natsal-COVID Wave 1: a large, quasi-representative survey with qualitative follow-up measuring the impact of COVID-19 on sexual and reproductive health in Britain](#) [version 2; peer review: 1 approved, 1 approved with reservations]

Emily Dema, Andrew J Copas, Soazig Clifton, Anne Conolly, Margaret Blake, Julie Riddell, Raquel Boso Perez, Clare Tanton, Chris Bonell, Pam Sonnenberg, Catherine H Mercer, Kirstin R Mitchell, Nigel Field
Peer Reviewers Jamie Frankis; Laura D Lindberg

Funders

Wellcome Trust

Economic and Social Research Council

National Institute for Health Research

Medical Research Council

University College London

Chief Scientist Office

LATEST VERSION PUBLISHED 28 Mar 2022

*

*

*

*

Think Tanks

Brookings

<http://www.brookings.edu/>

Accessed 02 Apr 2022

Essay

[The economic case for federal investment in COVID-19 vaccines and therapeutics remains strong](#)

Susan Athey, Rena M. Conti, Matthew Fiedler, Richard G. Frank, and Jonathan Gruber
Friday, April 1, 2022

Center for Global Development [to 02 Apr 2022]

<https://www.cgdev.org/>

Publications, Events [Selected]

Reexamining Global Health: Global Commons, Financing Priorities, and the Role of Institutions in the Global South

Event

3/28/22

The COVID-19 pandemic has showcased the large vulnerabilities of the global health architecture and weaknesses in the resilience of national health systems. It has also reinvigorated a debate about the right way to prioritize and use development assistance for health (DAH).

YouTube Recording: <https://youtu.be/yVotbI-93ek>

Chatham House [to 02 Apr 2022]

<https://www.chathamhouse.org/>

Accessed 02 Apr 2022

Pandemic: Needled by the rulebook

At last, there is a new proposal for a waiver on Covid-19 vaccine patents, but it is a far from useful compromise, says James Love

The World Today 1 April 2022

James Love, Director of Knowledge Ecology International

CSIS

<https://www.csis.org/>

Accessed 02 Apr 2022

[No new digest content identified]

Kaiser Family Foundation

https://www.kff.org/search/?post_type=press-release

Accessed 02 Apr 2022

March 28, 2022 *News Release*

Many Uninsured People Could Lose Access to Free COVID-19 Testing, Treatment, and Vaccines as Federal Funding Runs Out

With an impasse in Congress over additional COVID-19 emergency funding, uninsured people could lose access to free testing and treatment services, a new KFF brief explains. For people without health insurance, the Health Resources and Services Administration (HRSA) COVID-19 Uninsured Program has reimbursed hospitals, doctors and other providers for the...

Rand [to 02 Apr 2022]

<https://www.rand.org/pubs.html>

Reports, Selected Journal Articles

Report

Understanding Competition: Great Power Rivalry in a Changing International Order — Concepts and Theories

U.S. national security policy for the foreseeable future will likely be oriented around competition with China and Russia. The author reviews U.S. government strategy, RAND research, and other sources to help explain international competitions.

Mar 30, 2022

Michael J. Mazarr

* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy ([CVEP](#))/GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2022. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#); the Bill & Melinda Gates Medical Research Institute , [PATH](#), and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * *